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Platinum compounds, such as cisplatin, and oxaliplatin are utilised widely in 
therapeutic strategies against a range of malignancies, for instance Neuroblastoma 
and Ovarian cancer. These compounds elicit anticancer effects by damaging DNA via 
the formation of crosslinks with nitrogenous bases, leading to DNA damage responses 
and the induction of apoptotic signalling.  Although these compounds may produce 
promising initial responses, the emergence and establishment of chemoresistant 
tumour cells can often result in tumour relapses and treatment failure. The 
mechanisms driving resistance to platinum compounds are numerous, and act via a 
diverse range of cellular processes, such as reducing uptake of the drug, increasing 
DNA repair activity, and reducing apoptotic signalling.  
There are also research efforts to elucidate the epigenetic modifications of 
resistant tumours, and the means in which these changes are recognised and 
transduced. The Bromodomain and Extra-Terminal domain (BET) family of proteins 
recognise acetylated histones, and regulate transcription via association with 
transcriptional co-activators and RNA polymerase II. BET family members, such as BRDね┸ are able to form ╅super-enhancers╆┸ promoting oncogenic activity of genes such 
as MYC. Consequently, BET proteins have been identified as potential anticancer drug 
targets, prompting the development of BET inhibitors. 
This study investigated whether the BET inhibitors, JQ1 and I-BET726, were 
able to increase the sensitivity of parental and oxaliplatin-resistant Neuroblastoma 
(UKF-NB-3) and cisplatin-resistant Ovarian cancer cell lines (COLO-704, EFO-21 and 
EFO-27) to their respective platinum compounds. BET inhibitor pre-treatments, using 
the IC10 and IC50 concentrations of JQ1 and I-BET726 as single-agents for each cell 
line, resulted in increased sensitivity to the platinum compounds, as determined by 
MTT cell viability assays.  Increasing the pre-treatment incubation duration from 0hrs 
to 24hrs and 48hrs improved the response to platinum agents, and the same effect 
was observed with increasing pre-treatment dosage. In summary, these results 








2.1 Overview of Cancer 
2.1.1 Cancer Incidence and Survival Statistics 
Cancer is a prominent cause of death worldwide, with a rising number of cases as 
populations grow, with prolonged life expectancies, and the adoption of lifestyle 
choices which increase cancer risk. In 2012, there were approximately 14.1 milllion 
new cases of cancer worldwide, and there were 8.2 million cancer deaths globally 
(Torre et al., 2016). Incidence rates vary widely from country-to-country, with the 
highest incidences generally seen in Europe, North America and Oceania.  
In England in 2015, there were 299,923 registrations of newly diagnosed cases 
of cancer, and 134,679 deaths from cancer (Kaur & Poole, Office for National Statistics, 
2017).  The most frequently diagnosed cancer types were lung, colorectal, skin, breast 
and prostate cancer. In many cancer types there have been improvements in the 5-year 
survival rates throughout the past 10 years, however for many cancers the prognosis 
remains poor and there is a need for improved treatment strategies. For instance, data 
from 2001-2005 found the 5-year survival rate for lung cancer patients in England was 
7.4%, improving slightly with a rise to 13.8% in the 2010-2014 report, however this 
figure is still very low in comparison to tumours such as melanoma (90.7%) (Bannister, 
Office for National Statistics, 2017). 
 
2.1.2 Neuroblastoma 
Neuroblastoma is the most common extracranial solid tumour diagnosed in 
children (Salim et al., 2011). The disease affects mostly children under 5 years old , and 
around 100 children are diagnosed with neuroblastoma each year in the UK (Cancer 
Research UK, 2015).  
Neuroblastomas are formed of small, undifferentiated sympathetic neural 
precursor cells, known as neuroblasts. Over half of neuroblastomas present as tumours 
in the adrenal medlla, but tumours can often arise in the paraspinal ganglia in the 
abdomen, chest and pelvis (Brodeur, 2003). Patients with the disease often present 
with poor appetite, abdominal pain and distension, bruising, nausea and diarrhoea. 
Over half of the patients with neuroblastoma are diagnosed with metastatic disease, 
with the disease commonly spreading to the bones, skin, lymph nodes, and liver. 
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The prognosis for neuroblastoma is variable depending on the age and stage of 
disease at the time of diagnosis. There are also genetic features which subdivide the 
disease to either a low-risk neuroblastoma with a better prognosis, or a high-risk 
neuroblastoma which has a much poorer 5-year survival rate (PDQ® Pediatric 
Treatment Editorial Board, 2017).  
A key feature which has a strong influence on survival is the MYCN amplification 
status of the tumour, which gives a poorer prognosis across all age groups with any 
stage of disease (Ambros et al., 2009). MYCN is a transcription factor required for 
regulating the proliferation, differentiation and survival of neural cells in the 
developing neural crest. MYCN amplification (more than 10 copies per diploid genome) 
is seen in 22% of all neuroblastoma cases, and in 44% of high-risk neuroblastoma cases 
(Brodeur, 2003; Ambros et al., 2009). 
 
2.1.3 Ovarian Cancer 
The World Cancer Report 2014, produced by the World Health Organisation 
(Stewart & Wild, 2014), estimated that there were approximately 239,000 new cases 
of ovarian cancer worldwide in 2012, making the disease the seventh most common 
cancer of women globally. In the same year, ovarian cancer was accountable for around 
152,000 deaths. In the UK, there were 7,378 new cases of ovarian cancer in 2014, and 
4,128 deaths from the disease, making ovarian cancer the sixth most common cancer 
in females, and the fifth most common cause of female cancer death (Cancer Research 
UK). In the UK, the lifetime risk of developing ovarian cancer is about 1 in 60 (Jayson 
et al., 2014). 
Over 90% of ovarian cancers arise from the epithelial surface (Rosen et al., 2009), 
with germ cells and stromal cells each accounting for approximately 5% of the 
remaining cases. Epithelial ovarian cancers can be subdivided using the histopathology 
of tumour biopsies to identify predominant cell types/lineages. Epithelial tumours are 
classified (from most to least common) as serous, endometrioid, mucinous, clear cell, 
or undifferentiated.  Each of these sub-types have differing prognoses, with 5-year 
survival rates varying from 40‒69% for mucinous tumours, to 11‒29% for 
undifferentiated ovarian carcinomas (Rosen et al., 2009). 
Ovarian cancers can also be graded as low-grade or high-grade, based on the 
abundance of abnormal nuclei (atypia), and the presence of genetic mutations. 
Common mutations which are observed in high-grade ovarian carcinomas affect TP53, 
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BRCA1/2, P21WAF1, and C-MYC (Jayson et al., 2014; Plisiecka-Halasa et al., 2003). The 
consequences of such mutations are very proliferative tumours with high levels of 
genetic instability, resulting in increased likelihood of treatment failure and poorer 
prognoses for patients. 
   
2.2 Platinum Drugs and the Emergence of Resistance  
Cisplatin (cis-diamminedichloroplatinum II) is a member of a group of 
compounds which characteristically feature platinum as the central component of a 
complex (Figure 1ょ┻ )nitially ゅduring the なひはど╆sょ┸ it was found that cisplatin was 
effective in inhibiting the growth of E.coli and, during the なひばど╆s┸ further studies of 
experimental tumour cell lines suggested that cisplatin may prove to be an effective 
anti-cancer agent, and therefore a number of clinical trials were initiated (Prestayko et 
al., 1979). These studies demonstrated antitumour activity across a range of 
malignancies, including neuroblastoma and ovarian cancer, as well as other tumours 
such as head and neck cancer and lung cancer. 
As a general overview of its mechanism, cisplatin functions by interacting with 
DNA, particularly targeting the purine bases, Adenine and Guanine. This interaction 
forms DNA adducts, such as inter- or intra-strand ApG and GpG crosslinks (Siddik, 
2003). These DNA adducts induce cell cycle arrest, inhibited DNA synthesis and 
transcription of RNA, and the upregulation of pro-apoptotic signalling pathways. 
Specific features of the cisplatin mechanism of action shall be discussed in the context 
of chemoresistance to the compound (Section 2.3).  
The nature in which cisplatin targets tumours means that the drug has also been 
shown to cause a number of side effects in the kidneys (nephrotoxicity), nervous 
system (neurotoxicity) and inner ear (ototoxicity) (Galluzzi et al., 2012). However, the 
main factor limiting the efficacy of cisplatin therapy is the emergence of 
chemoresistance. Chemoresistance may be acquired over time as an adaptive response 
to prolonged exposure to the compound, or cells may display intrinsic resistance. 
Figure 1: The structures of Cisplatin, Carboplatin and Oxaliplatin, produced using Advanced Chemistry 
Development, Inc. (ACD/Labs) ChemSketch software. 
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Consequently, cisplatin resistance is responsible for the high relapse rates and the 
greatly reduced 5-year patient survival rates seen in ovarian cancers and non-small 
cell lung cancer (NSCLC) (Siddik, 2003). 
In response to the emergence of cisplatin resistance, and in an attempt to mitigate 
some of the side effects to cisplatin, the compounds carboplatin (cis-diammine 
(cyclobutane-1,1-dicarboxylate-O┸O╆ょ platinumゅ))ょ ょ and oxaliplatin ゅ いゅなR┸にRょ-
cyclohexane-1,2-diamine](ethanedioato-O┸O╆ょ platinumゅ))ょ ょ have been developed┻ 
Carboplatin was found to induce less severe side effects, however the drug has less 
potency, and functions using the same mechanism as cisplatin so is susceptible to the 
same resistance issues (Harrap, 1985). Oxaliplatin was subsequently developed, with 
a distinct pharmacological and immunological profile to cisplatin. Evidence suggests 
that cisplatin-resistant tumours may be susceptible to oxaliplatin, however a degree of 
cross-resistance has been observed (Stordal et al., 2007).   
 
2.3 Mechanisms of Chemoresistance to Platinum Compounds 
Due to the significant clinical impact of cisplatin resistance across a wide range 
of malignancies, a large volume of research has been conducted to characterise the 
mechanisms driving chemoresistance, and investigate means to negate the issue.  
The traits which promote resistance to platinum compounds can be broadly 
grouped into three categories: those which restrict the cisplatin-DNA interaction, those 
which give increased repair to the DNA damage caused by the compound, and 
adaptations which are able to reduce the anti-tumour signalling pathways induced by 
platinum compounds. 
 
2.3.1 Inhibiting the Cisplatin-DNA Interaction 
One way of promoting survival in the presence of cisplatin is to reduce the uptake 
of the compound. Resistant cell lines have been seen to show a decreased accumulation 
of cisplatin within the cell, a mechanism of pre-target resistance. One aspect of this 
reduced accumulation is likely due to reduced influx of cisplatin into the cell. A study 
by Holzer et al. (2006) found that the uptake of cisplatin into a cell is closely associated 
with the expression of Copper Transporter 1 (CTR1) (Figure 2). Wild type (+/+) CTR1 
cells showed normal influx of copper, as well as platinum drugs. Conversely CTR1 
depletion (-/-) reduced drug uptake, leading to approximately 3-fold increases in 
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cisplatin resistance. CTR1 was seen to be downregulated in cisplatin-resistant cell 
lines. 
 Additionally, chemoresistance may arise from increased efflux of platinum 
compounds from the cell. Copper homeostasis transporters have again been implicated 
in chemoresistance via the increased efflux of platinum compounds. Safaei et al. (2004) 
observed that the P-type ATPase copper efflux transporters, ATP7A and ATP7B, were 
expressed at higher levels in tumour cell lines selected for resistance to cisplatin, 
oxaliplatin, and carboplatin. Cell lines with higher ATP7A and ATP7B expression were 
also found to have less DNA damage in response to treatment with platinum 
compounds. In many human cancers, the transport proteins, P-glycoprotein (P-gp, also 
known as ABCB1) and multidrug-resistant proteins (MRPs, also known as the ABCC 
family) are commonly seen to be overexpressed leading to resistance to a range of 
compounds. However there are exceptions, for instance, acquired multi-drug 
resistance in neuroblastoma cell lines was found to occur independently of P-gp 
expression (Kotchetkov et al., 2005). 
 Increases in the levels of cytoplasmic thiol-containing compounds such as 
glutathione or metallothioneins is another means by which cells can detoxify platinum 
compounds, thus preventing subsequent interactions with DNA (Kelland, 2007). These 
compounds contain sulphur groups which facilitate the binding of the platinum 
compounds. This interaction produces inactive conjugates which can then be expelled 
from the cell. Kasahara et al. (1991) analysed and compared the levels of 
metallothioneins in non-small cell lung cancer cell lines displaying 6- and 11-fold 
resistance to cisplatin, finding a positive correlation between metallothionein content 
and the degree of resistance (determined by changes in the IC50).  
 
2.3.2 Repair of Cisplatin-DNA Adducts 
Evidence suggests that a source of cisplatin susceptibility lies in the competency 
of DNA repair mechanisms within a cell line. For example, in malignancies such as 
Figure 2: An overview of the transporters thought to be involved in cisplatin influx or efflux 




testicular cancer which seem to show deficiencies in DNA repair, there appears to be 
reasonable levels of susceptibility to cisplatin. By contrast, less responsive cell lines 
such as ovarian cancer appear to exhibit more proficient DNA repair (Kelland, 2007). 
Nucleotide excision repair (NER) is a vital mechanism in the repair of DNA 
damage and therefore it was postulated to have a role in platinum resistance. Studies 
have shown that the excision repair cross-complementation group 1 (ERCC1) enzyme 
is involved in the repair of cisplatin-induced DNA adducts, using its ability to repair 
inter-strand crosslinks (Olaussen et al., 2006). ERCC1-positive non-small cell lung 
cancer cell lines were found to be less responsive to cisplatin adjuvant therapy 
compared to ERCC1-negative cell lines. This led to the hypothesis that ERCC1 
expression could be examined in resected tumours, and used as a predictor of success 
with subsequent adjuvant therapy.    
Another DNA mechanism, mismatch repair (MMR), is required for the 
recognition and repair of DNA damage, as well as the coupling of this recognition with 
cell cycle arrest, and pro-apoptotic signalling┻ Subunits of the MutLゎ-mismatch repair 
complex, hMLH1 and hPMS2, were found to show reduced expression in cisplatin-
resistant ovarian cancer cell lines (Brown et al., 1997). Cell lines showing deficient 
mismatch repair were seen to be more tolerant to DNA damage, and lost the ability to 
induce G1 and G2 cell cycle arrest. In cells with functional hMLH1, cells are able to 
recognise DNA adducts, and induce cell cycle arrest and apoptosis, which suggests that 
hMLH1 depletion allows for survival by negating the DNA lesion or failing to induce 
signalling pathways.  
Due to structural differences between cisplatin and oxaliplatin, namely the larger 
size and presence of the diaminocyclohexane group of oxaliplatin, it is thought that 
ERCC1 plays a key role in the processing of (and resistance to) oxaliplatin, but changes 
in MMR do not seem to contribute to oxaliplatin resistance (Seetharam et al., 2009).        
 
2.3.3 Alterations in Signalling 
 The most prominent pathway linking DNA damage to apoptosis is the activation 
of the ataxia telangiectasia mutated (ATM)- and RAD3-related protein (ATR), which is 
able to act as a sensor of DNA damage. Upon activation, ATR is able to phosphorylate 
the downstream effector, checkpoint kinase 1 (CHEK1), which itself is able to provide 
activating phosphorylations to p53 (Shieh et al., 2000; Zhao and Piwnica-Worms, 
2001). Additionally, ATR is able to phosphorylate the histone H2A variant, H2AX, at 
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Ser-なぬひ to generate ぐ-H2AX. This phosphorylation occurs not just within the 
immediate vicinity of the DNA lesion, but spreads throughout the proximal chromatin to create a ぐ-(にAX focus which acts as a ╅launch-pad╆ for DNA damage response 
signalling (Kinner et al., 2008┹ Pabla et al┻┸ にどどぱょ┻ As a consequence┸ ぐ-H2AX is a useful 
biomarker which is frequently used for the study of DNA damage and repair (Mah et 
al., 2010).  
 Cisplatin induces p53 to activate a number of 
downstream genes, leading to cell cycle arrest and 
apoptosis. In a study of ovarian cancer patients, wild-
type p53 status predicted a better clinical outcome 
than patients expressing mutated p53 (Gadducci et al., 
2002). This study also found that paclitaxel induces 
apoptosis independently of p53, and so could prove to 
be a useful treatment in such instances. A study of 
metastatic colorectal cancer cell lines (Yang et al., 
2016) found a similar result: cells with wild-type p53 
showed sensitivity to oxaliplatin, and those with 
defective p53 showed resistance. This study observed 
an accumulation of p53 after treatment with 
oxaliplatin, as well as upregulation of the cytochrome enzyme┸ CYPにSな┸ leading to downregulation of Wnt【が-
catenin and PGE2 signalling pathways. Additionally, 
knockdowns of CYP2S1 resulted in increased 
proliferation and cell survival after oxaliplatin treatment, illustrating the importance 
of the cytochrome enzymes in mediating the response to oxaliplatin. 
Bcl-2 is an inhibitor of apoptosis, and is commonly overexpressed in a number of 
malignancies such as leukaemias and neuroblastoma. Neuroblastoma cell lines 
expressing higher levels of Bcl-2 were found to show resistance to cisplatin (Dole et al., 
1994). Bcl-2 expression was observed in approximately a third of pre-therapy 
neuroblastoma specimens, with this proportion increasing to approximately 80% of 
specimens provided post-cisplatin therapy. Higher Bcl-2 levels provide greater 
tolerance to the cytotoxic cisplatin-induced DNA damage by inhibiting apoptosis. 
A signalling network which appears to be distorted in cisplatin-resistant cells are 
the mitogen-activated protein kinase (MAPK) pathways. Research investigating the 
Figure 3: A simplified depiction 
outlining some of the mechanisms 
by which cisplatin-induced DNA 
damage is coupled to apoptosis. 
This schematic is focused largely 
on elements shown to be modified 
in resistant cell lines. Produced 





cisplatin-induced activation of the JNK, P38 and ERK pathways in ovarian carcinoma 
cell lines (Mansouri et al., 2003) yielded varying activation patterns between sensitive 
and resistant cell lines. Sensitive cell lines showed prolonged (8 to 12 hours) activation 
of the JNK and P38 pathways in response to cisplatin, whereas resistant cells showed 
only transient (1 to 3 hours) activation. Blocking the activation of JNK and P38 in 
resistant cell lines inhibited apoptosis in response to cisplatin. Chemoresistance was 
associated with an inability to upregulate the pro-apoptotic Fas-ligand. Prolonged 
activation of the JNK pathway is implicated with increased Fas-ligand expression, and 
therefore the duration of signal activation appears to be key in producing apoptosis.  Wnt【が-catenin signalling is derailed in a number of diseases (including cancers, Alzheimer╆s disease┸ and metabolic diseaseょ┻ Wnt signalling regulates a number of 
critical genes such as cyclin D1, c-Myc, survivin, and the ABC transporters Multidrug 
Resistance Protein 4 (MRP4) and Breast Cancer Resistance Protein (BCRP). A key regulator of Wnt【が-catenin signalling is dishevelled, which acts downstream of the Frizzled receptor to modulate GSKぬ and allow for が-catenin to accumulate in the nucleus┻ (igh levels of dishevelled blocks が-catenin destruction and therefore leads to 
activation of target genes. A study of alveolar adenocarcinoma cell lines found that the 
DVL2 gene is overexpressed in cisplatin-resistant cell lines (Luo et al., 2016). Inhibition 
of DVL2 was shown to restore sensitivity of these resistant cell lines to cisplatin. 
Additionally, the genes for BCRP and MRP4 were stronger expressed in resistant cell 
lines, with reductions seen after DVL2 inhibition.   
Analysis of tumours from rat models found that expression of the c-Myc oncogene 
was approximately doubled in cells post-cisplatin treatment (Walker et al., 1996). c-
Myc plays a key role in increasing cell proliferation, mitogenesis, and reducing 
differentiation and apoptotic cell death signalling, increasing the tolerance to cisplatin.  
Growth factor receptors can also be upregulated in resistant tumours, leading to 
increased proliferation and a pro-survival response. The epidermal growth factor 
receptor (EGFR) is frequently expressed in neuroblastoma cell lines, and was found to 
have increased expression in cell lines showing chemoresistance to cisplatin (Michaelis 
et al., 2008). Resistant cell lines were found to be susceptible to anti-EGFR toxins, even 
in cell lines that were insensitive to the anti-EGFR antibody, cetuximab. Resistant cell 
lines showed increased EGFR expression even after several passages in the absence of 
cisplatin, suggesting that these upregulations are stable. Combinations of cisplatin and 
either of the anti-EGFR toxins produced potent anti-cancer effects; significantly 
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stronger than either treatment alone. EGFR is able to induce signalling via the PI3-K 
and PKB/Akt pathway. It was found that inhibition of PI3-K resulted in increased 
sensitivity to cisplatin in pancreatic and breast cancer cell lines, suggesting that 
increases in PI3-K and PKB/AKT signalling may provide resistance to cisplatin 
(Winograd-Katz and Levitzki, 2006). 
Drug resistant cells show accelerated tumour progression, with a shift towards a 
more invasive and migratory phenotype, using shifts in the expression of cell adhesion 
receptors and pro-angiogenic factors, something which may be a product of the 
widespread alterations in signalling (Blaheta et al., 2006; Michaelis et al., 2009). 
 
2.4 The Bromodomain and Extra-Terminal Domain (BET) Family 
2.4.1 Overview of BET Family 
As well as studying genetic mutations which may be involved in tumourigenesis, 
there is an increase in research assessing the role epigenetic regulatory mechanisms in 
tumourigenesis (such as aberrant methylation patterns, deregulated 
acetylation/deacetylation, and altered recognition of modified chromatin).  
Acetylation of lysine residues at the N-terminus of histone tails is a modification 
which is generally associated with transcriptionally active euchromatin. The 
recognition of acetyl-lysine residues is primarily by proteins containing 
bromodomains (BRD), such as those from the BRD and Extra-Terminal domain (BET) 
family, consisting of BRD2, BRD3, BRD4, and the testis-specific BRDT (Filippakopoulos 
and Knapp, 2014).        
BET proteins characteristically feature two N-terminal tandem bromodomains 
(BRDs), consisting of a four-helix bundle ゅゎZ┸ ゎA┸ ゎB and ゎCょ linked by diverse ZA and 
BC loop regions (Wang and Filippakopoulos, 2015). The BC loop contains a conserved 
asparagine residue which is critical for the interaction of BET proteins with the acetyl-
lysine of histone 4.  BET proteins also feature well-conserved A, B and SEED 
(Ser/Glu/Asp) motifs (Figure 4). The A motif contains a nuclear localisation sequence 
Figure 4: A generalised overview of the structure of a BET family protein, consisting of two 
bromodomains (BD - green), A, B and SEED (Ser/Glu/Asp) motifs (red), an extraterminal domain (ET ‒ 




of 12 amino acids (KGVKRKADTTTP), and the B motif is thought to be important in 
facilitating homo- or heterodimerisation of BET proteins. BET proteins are also typified 
by the presence of a helical extra-terminal (ET) domain, which is preserved between 
the four BET family members. 
 
2.4.2 Action of BET Family Proteins  
Upon binding acetylated histone tails, BET proteins are able to modify 
transcriptional activity by facilitating the association of a number of transcription 
factors, co-activators or co-repressors.  A key interaction which facilitates this function 
is the association of BRD4 with the positive transcription elongation factor, P-TEFb, 
which is comprised of a heterodimer between Cdk9 and cyclin T1 (Yang et al., 2005). 
P-TEFb is essential for regulating transcriptional elongation by RNA Pol II, and is 
therefore crucial for ensuring the strict co-ordination of gene expression. P-TEFb is 
often seen in a sequestered, inactive state, by forming complexes with regulatory 7SK 
snRNA and the HEXIM1 protein. Yang et al. (2005) demonstrated that P-TEFb 
associates with the C-terminal domain of BRD4 to become transcriptionally active, 
recruiting RNA Pol II. BRD4, via its association with acetyl-lysine residues of histones, 
is therefore able to ensure that P-TEFb (and subsequently RNA Pol II) are localised at 
transcriptionally active euchromatin sites.  
BRD4 has also been found to recruit P-TEFb independently of histones via an 
interaction with the Mediator complex (Yang et al., 2005; Basheer and Huntly, 2015). 
Mediator acts as a co-activator, enabling transcription factors to interact with RNA Pol 
II. BRD4 is able to interact with the MED1 subunit (also known as TRAP220) at 
transcription start sites, further highlighting an important role of the BRD4-Mediator 
interaction to regulate transcription. 
Studies have shown that BRD4 plays a key role in the progression of the cell cycle. 
During mitosis a cell must facilitate a transcriptional shutdown, via the dissociation of 
transcription factors and coiling of chromatin to give gene silencing. Some genes must 
remain marked, however, to ensure that the transcription of appropriate genes (such 
as the key M/G1 genes expressed after mitosis) can be inherited in daughter cells. This 
marking is facilitated by the association of BRD4, which allows for P-TEFb association 
and subsequent transcription via RNA Pol II (Dey et al., 2009). BRD4 marking was not 
seen in genes required at later stages of the cell cycle, suggesting that this marking is 
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purely to ensure the cell cycle progresses post-mitosis, upon which BRD4 can assume 
its dynamic role in regulating global transcriptional activity.  
A large amount of the research into BET family proteins has focused on the 
interactions of the bromodomain with chromatin, or the interaction of the C-terminal 
domain with P-TEFb. The extraterminal domain of this protein family is highly 
conserved, and therefore studies have used proteomics to investigate a role of the 
extraterminal (ET) domain. Five proteins were found to interact with the ET domain of 
BRD4: NSD3, CHD4, JMJD6, GLTSCR1, and ATAD5 (Rahman et al., 2011), and these 
interactions are also conserved with BRD2 and BRD3. NSD3, JMJD6 and GLTSCR1 were 
found to combine with BRD4 to play a role in transcriptional regulation in a pTEFb-
independent manner. The five proteins each have been found to play a role in the 
regulation of chromatin structure and activity. The association of BRD4/NSD3 was 
found to be implicated with H3K36 methylation, and so has a role in modifying the 
epigenetic environment surrounding BRD4 targeted genes. 
BET proteins are able to interact directly with a range of transcription factors, 
including p53, c-Jun and c-Myc/Max (Wu et al., 2013). BRD4 has the ability to recruit 
these factors to transcriptionally active regions containing acetylated histones, 
providing a regulatory mechanism for their activity. BRD4 may also regulate the 
function of these proteins independently of histones, for example the binding of BRD4 
to c-Myc appears to also modulate c-Myc protein stability and activity.  
 
2.4.3 Role in Disease 
As the BET family of protein are able to function via a number of mechanisms, 
and can therefore regulate a range of pathways, it has been observed that alterations 
in BET activity is associated with a number of diseases, such as cancer or inflammatory 
diseases. For example, high levels of BRD2 have been seen in human leukaemias and 
B-cell lymphomas, and chromosomal translocations can produce fusions of BRD4 or 
BRD3 with nuclear protein in testis (NUT), causing NUT midline carcinomas (NMCs) 
(Wang and Filippakopoulos, 2015; Zhang, Su et al., 2016). A study assessing the effects 
of BET mutations, particularly mutations commonly observed in cancers, found that 
mutations were seen to generally cause a decrease in overall stability, and give a 
flexibility to the tertiary structure (Lori et al., 2016). The mutations occurred in close 
proximity to the acetyl-lysine binding site which may alter histone binding affinities. 
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Mutations giving flexibility and loosened tertiary structure may also possibly facilitate 
alternative interaction networks by exposing new sites.   
  
2.5 BET Inhibitors as Cancer Therapeutics 
2.5.1 Rationale Behind BET Inhibitors and Their Mechanism of Action 
In addition to changes in the BET proteins themselves, many of the pathways 
regulated by BET proteins are deregulated in cancer, for example c-Myc and p53 
signalling. Therefore, it was postulated that inhibitors of BET proteins could provide 
therapeutic benefits in these diseases. 
A number of studies have used RNA interference by short hairpin RNA (shRNA) 
or small interfering RNA (siRNA) to inhibit BET proteins. Inhibition was found to result 
in arrest of the cell cycle and pro-apoptotic affects in NUT midline carcinoma (NMC) 
and acute myeloid leukaemia cell lines (French et al., 2008; Zuber et al., 2011). These 
studies provide proof-of-concept that BET inhibition could potentially be a viable 
strategy in cancer chemotherapy.  
A number of compounds have been developed as inhibitors of BET proteins, 
including JQ1, I-BET151, MS417, and PFI-1 (Zhang, Su et al., 2016; Filippakopoulos et 
al., 2010). These function by competitively binding the acetyl-lysine recognition motifs, 
thus inhibiting BET recruitment to chromatin and causing repression of downstream 





2.5.2 Uses of BET Inhibitors in Cancer Research  
Zhang et al. (2016) observed that JQ1 impaired the malignant transformation of 
mouse skin epidermal JB6 P+ cells after treatment with the tumour promoter 12-O-
tetradecanoylphorbol-13-acetate (TPA). Similarly, the study by Filippakopoulos et al. 
(2010) noted that JQ1 was able to induce cellular differentiation, phenotypic changes 
to flattened, squamous shapes, with reduced proliferation and increased apoptosis.  
Figure 5: JQ1 is able to competitively bind the acetyl-lysine recognition domains of BRD4, leading to 
displacement from histones and inhibited transcription of target genes.  
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BET proteins are expressed widely across many tissue types, and therefore it 
might be expected that inhibition could cause widespread toxicity. However, in mouse 
models, the mice showed tolerance to BET inhibitors at dosages capable of causing 
tumour inhibition. It has been determined that the disproportionate clustering of BRD4 
and mediators at super-enhancer regions is responsible for driving the activity of a 
number of key cancer genes, such as the MYC oncogene. Super-enhancer sites were 
found to be more susceptible to JQ1 treatment than typical enhancers, with JQ1 
inducing preferential loss of BRD4 at these sites (Loven et al., 2013). Consequently, 
additional co-factors (such as MED1 and CDK9) were also lost from the super-enhancer 
as a result of the decrease in BRD4 association. 
As mentioned previously, BET proteins have been found to interact with and 
regulate c-Myc activity. MYC is one of the most commonly mutated genes observed in 
human cancers, causing increased cell proliferation,  altered metabolism, and 
preventing terminal differentiation. Genetic studies in mice found that inactivation of 
MYC transcription can lead to regression of tumours. However, MYC lacks domains 
which are suitable to give specificity for drug targets e.g. binding sites for competitive 
or allosteric inhibitors. It was found (Delmore et al., 2011) that BRD4 inhibition is able 
to inhibit c-Myc signalling, reducing proliferation and inducing cell cycle arrest and 
apoptosis in multiple myeloma. The compounds I-BET151 and I-BET762 were both 
also found to downregulate c-Myc in multiple myeloma cell lines, as well as 
upregulating the HEXIM1 negative regulator of pTEFb (Chaidos et al., 2014).   
This effect is similarly seen in neuroblastoma, a malignancy which frequently 
exhibits overexpression of n-Myc (Ambros et al., 2009; Puissant et al., 2013). BET 
inhibitors produced downregulation of MYCN transcription and suppression of 
downstream n-Myc pathways in neuroblastoma, leading to reduced tumour cell 
proliferation and pro-apoptotic effects. BET inhibitors have been found to 
downregulate MYC activity in a number of additional tumours, such as non-small cell 
Typical enhancer-driven gene Super-enhancer driven oncogene (e.g. MYC) 
Figure 6: The interaction between BRD4 with a typical enhancer-driven gene (left), compared with a super-
enhancer produced by the aggregation of BRD4, resulting in elevated transcription (right). 
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lung cancer┸ prostate cancer and Burkitt╆s lymphoma ゅWang and Filippakopoulos┸ 
2015).  
Studies in glioblastoma and B-cell lymphoma have shown that BET inhibitors 
may also work in a Myc-independent manner. JQ1 treatment of glioblastoma resulted 
in notable changes in expression of p21WAF1, Bcl-2 and Bcl-xL, resulting in cell cycle 
arrest and apoptosis (Cheng et al., 2013). A study of B-cell lymphoma observed 
upregulation of the pro-apoptotic Bim, and downregulation of the anti-apoptotic Bcl-2 
and Bcl-xL (Hogg et al., 2016). Notably, both studies found that JQ1 was able to induce 
apoptosis independently of p53 expression, a feature which is commonly derailed in 
cancer. 
The PI3-K pathway is crucial for regulating a range of substrates key to 
modulating cell growth, metabolism, proliferation and survival, and is commonly 
disordered in cancers. However, there is emerging resistance to PI3-K inhibiting drugs, 
particularly to isoform-specific inhibitors of PI3-K. Other PI3-K isoforms have been 
shown to compensate for each other, and activation of separate, compensatory 
pathways has also been observed as a means of generating resistance. Recent studies 
have shown that BET inhibitors are able to counteract the resistance mechanisms to 
PI3-K inhibitors that would otherwise limit the efficacy of the treatments 
(Stratikopoulos and Parsons, 2016). In addition, BET inhibitors may cause reductions 
in signalling via the MAPK, JAK/STAT, and oestrogen receptor pathways, and therefore 
be useful as part of combinatorial treatment plans.  
 
2.6 Project Aims 
A number of the genes targeted by BET inhibitors are seen to be deregulated in 
tumours exhibiting resistance to cisplatin and other platinum compounds (coding for 
proteins such as c-Myc, Bcl-2, PI3-K, MAPK). This research project investigated the 
possibility that treatment with BET inhibitors would prove effective against parental 
and platinum-resistant neuroblastoma and ovarian cancer cell lines, and whether pre-
treating with BET inhibitors would increase the sensitivity to platinum compounds in 






3. Materials and Methods 
3.1 Compounds 
3.1.1 Platinum Compounds 
Cisplatin (Sigma, Poole, Dorset, UK, Ref P4394) was dissolved in 0.9% sodium 
chloride, to produce a stock solution of 1mg/mL (3.33mM). Cisplatin was dissolved in 
the dark at room temperature for 5 days using a magnetic stirrer. At this point the 
solution was filter sterilised (0.2 micron), with all filter sterilisation taking place in a 
Class II biological safety cabinet (BioMAT 2, Contained Air Solutions, Manchester, UK) 
to ensure sterility before using cisplatin for mammalian cell culture. The solution was 
aliquoted into sterile tubes and stored at room temperature in the dark, due to the 
sensitivity of cisplatin to light.   
Oxaliplatin (Sigma, Poole, Dorset, UK, Ref O9512) was dissolved using filter-
sterilised (0.2micron) 5% (w/v) glucose solution, to produce a 1mg/mL stock solution 
(2.52mM).  This solution was aliquoted in to sterile tubes, stored at -20°C, and was also 
kept in the dark. 
 
3.1.2 BET inhibitors 
JQ1 (Cambridge Bioscience, Cambridge, UK, Ref CAY11187) was dissolved in 
Dimethyl Sulfoxide (DMSO) (Sigma, Poole, Dorset, UK, Ref D2438), to produce a stock 
solution of 1mg/mL (2.19mM).  I-BET726 (Cambridge Bioscience, Cambridge, UK, Ref 
CAY16872) was also dissolved in DMSO, to produce a stock solution of 1mg/mL 
(2.30mM).  Both compounds were aliquoted into sterile tubes and stored at -20°C. 
 
3.2 Tissue Culture 
3.2.1 Cell Lines and Growth Conditions 
The human neuroblastoma cell line, UKF-NB-3, was derived from bone marrow 
metastases of a patient with MYCN-amplified stage 4 neuroblastoma (Kotchetkov et al., 
2005). Drug resistant cell lines, established by continuous exposure to increasing drug 
concentrations, were obtained from the Resistant Cancer Cell Line (RCCL) collection 
(www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.html). An oxaliplatin-resistant UKF-
NB-3 cell subline had been established by adapting UKF-NB-3 to growth in the 
presence of oxaliplatin (2000ng/mL) and designated as UKF-NB-3rOXALI2000.  
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Cisplatin-resistant sub-lines of the ovarian cancer cell lines COLO-704, EFO-21 
and EFO-27 had been generated in the same way and were termed COLO-
704rCDDP1000, EFO-21rCDDP2000, and EFO-27rCDDP2000.  COLO-704 is a cell line of high 
grade serous adenocarcinoma, established from ascites fluid stemming from the colon 
metastasis of a 46-year-old woman in 1986. EFO-21 was established in 1979 from the 
ascitic fluid of a 56-year-old woman with dedifferentiated serous cystadenocarcinoma. 
EFO-27, also established in 1979, was established from the solid omental metastasis of 
a 36-year-old woman with mucinous papillary adenocarcinoma. 
All cell lines were cultured in )scove╆s Modified Dulbecco╆s Medium ゅ)MDMょ 
(Gibco, as part of Thermo Fisher Scientific, Loughborough, Leicestershire, UK, Ref 
12440061) supplemented with 100 U/mL penicillin/100 µg/mL streptomycin (Gibco, 
as part of Thermo Fisher Scientific, Loughborough, Leicestershire, UK, Ref 15140) and 
10% Foetal Bovine Serum (FBS) (Sigma, Poole, Dorset, UK, Ref F7524). The media for 
the drug-resistant cell lines were additionally supplemented with either oxaliplatin or 
cisplatin to the required concentrations, using the stocks outlined in Section 3.1.1. The 
cells were cultured in T25cm2 flasks (Sarstedt AG & Co, Sarstedtstraße 1, 51588 
Nümbrecht, Germany, Ref 83.3910.002) containing 10mL of media, which were kept in 
an incubator set at 37°C and 5% CO2 (ThermoForma Series II water jacketed CO2 
incubator, Thermo Fisher Scientific, Loughborough, Leicestershire, UK). The cell lines 
were always handled in a Class II biological safety cabinet, and only one cell line was 
used at any one time. 
 
3.2.2 Passaging of Cell Lines 
The UKF-NB-3, EFO-21 and EFO-27 sets of cell lines are all adherent, whereas the 




Adherent Cell Lines: 
To passage the adherent cells for maintenance and/or experiments, the following 
procedure was utilised. The media of the cells was aspirated using a 10mL serological 
pipette, and then the cells were washed with 2mL of Phosphate Buffered Saline (PBS) 
(OxoidTM Dulbecco A solution, without Ca2+ or Mg2+) (Fisher Scientific, as part of 
Thermo Fisher Scientific, Loughborough, Leicestershire, UK, Ref BR0014G). 
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The UKF-NB-3 cell lines were dissociated from the flask using 1mL of 0.05% 
Trypsin-EDTA (Gibco, as part of Thermo Fisher Scientific, Loughborough, 
Leicestershire, UK, Ref 25300054) for 2 minutes in a 37°C/ 5% CO2 incubator. The EFO-
21 and EFO-27 cell lines adhere much stronger, and so were instead dissociated using 
1mL of the more concentrated Trypsin-EDTA (1X) (Sigma, Poole, Dorset, UK, Ref 
59430C), spending 20 minutes in the 37°C/ 5% CO2 incubator.  Cells were then 
suspended in 10mL of media to cease the enzymatic reaction and allow for the 
passaging and/or plating of cells at appropriate densities. Separate media, PBS and 
Trypsin were used for each cell line to help prevent contamination. Cell lines were 
passaged after reaching a confluency of approximately 70-80%, and typically the cell 
lines were split at a ratio of 1 in 50 to give weekly passage intervals.           
 
Suspension Cell Lines: 
To passage the COLO-704 set of cell lines for maintenance and/or experiments, 
the following procedure was utilised. The cells (suspended in media) were aspirated 
using a 10mL serological pipette, and this suspension was centrifuged (Centaur 2, MSE 
UK Ltd, London, UK, Ref MSB020.CX1) at 1200rpm for 5 minutes to form cell pellets. 
The supernatants were removed and the cells were resuspended in 10mL of new 
media. The appropriate volume of cell suspension could then be added to a new flask 
for passaging and/or to plates at the appropriate densities for assays. As with the 
adherent cell lines, the COLO-704 lines were passaged after reaching a confluency of 
approximately 70-80%, and typically the cell lines were split at a ratio of 1 in 50 to give 












3.3 MTT Cell Viability Assay 
3.3.1 Assay Premise 
This assay uses (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) to measure metabolic activity as a marker of viable cells. Viable cells with active 
metabolism are able to convert the MTT (with a yellow colouration) into the purple-
coloured (E,Z)-5-(4, 5-dimethylthiazol-2-yl)-1,3-diphenylformazan (formazan) via 
mitochondrial activity (Figure 7). This allows for colourimetric assessment of cell 
viability by measuring the absorbance at 600nm.    
The MTT assay was used to assess the viability of the cancer cell lines after being 
challenged with platinum drugs or BET inhibitors as single agents, to establish dose-
response profiles, and determine the IC50 and IC90 for each cell line to the drugs. The 
cell lines would then be pre-treated with the BET inhibitors to determine whether this 
alters their sensitivities to platinum compounds (detailed further in Section 3.3.5). 
Concentrations of drug which are able to inhibit cell viability would result in less 
conversion of MTT to formazan and therefore lower absorbance at 600nm, relative to 
untreated cells.    
 
3.3.2 MTT Plate Setup 
 The MTT assays were always set-up in a Class II biological safety cabinet and the 
assays were arranged using a 96-well plate to give 8-point serial dilutions of drug. Each 
concentration of a particular drug was plated in triplicate wells, to give 3 technical 
repeats per plate. The plates also had media-only wells containing no cells (termed MIN ‒ outlined with blue in Figure 8), and wells containing cells and media in the absence 
of drug (termed MAX ‒ outlined with red in Figure 8). These allowed for the establishment of relative cell viability┸ and for the elimination of any ╅background╆ 
Figure 7:  The reduction of MTT to formazan via mitochondrial metabolism. (Brescia and Banks, 2009) BioTek 
Instruments, Inc., Winooski, VT 
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absorbance values produced from the media. Each well of the plate was made up to a total volume of などどづL┻ The 96-well assay plates were set up using the following 
protocol (Figure 8A-C).  
A ‒ Complete IMDM media added to outer wells, and to MIN and MAX wells 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 100 100 100 100 100 100 100 100 100 100 100 100 
B 100 50         100 100 
C 100 50         100 100 
D 100 50         100 100 
E 100 50         100 100 
F 100 50         100 100 
G 100 50         100 100 
H 100 100 100 100 100 100 100 100 100 100 100 100 
 
B ‒ Cells added (at 5000 cells per well) to sample and MAX wells 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B  50 50 50 50 50 50 50 50 50   
C  50 50 50 50 50 50 50 50 50   
D  50 50 50 50 50 50 50 50 50   
E  50 50 50 50 50 50 50 50 50   
F  50 50 50 50 50 50 50 50 50   
G  50 50 50 50 50 50 50 50 50   
H             
 
C ‒ Drug added ゅのどづLょ at にx concentration to adjust for dilution by cells in media 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B   1 2 3 4 5 6 7 8   
C   1 2 3 4 5 6 7 8   
D   1 2 3 4 5 6 7 8   
E   1 2 3 4 5 6 7 8   
F   1 2 3 4 5 6 7 8   
G   1 2 3 4 5 6 7 8   
H             
The procedure for counting cells is outlined in the subsequent section (3.3.3), and 
was used after passaging the confluent (70-80%) cell lines to ensure that 5000 cells 
Figure 8 : The protocol for setting up an MTT assay using a 96 well plate. A) Initially complete IMDM media was added 
to the outermost wells  to prevent evaporation of sample wells, and also added to the media-only (MIN) wells (blue 
outline) and to the untreated cell ゅMAXょ wells ゅred outlineょ┻ Numbers represent the volume of media ゅin づL added per 
well)  B) At this stage, the suspension of cells in media was added to the MAX wells, and to the experimental wells (B3-
G10). Prior to this, the cells had been passaged and counted to ensure that ひねねね cells would be present in the ひねづL added 
to each well. Cょ ひねづL of drug was added to each well┸ to give an ふ-point serial dilution, which is triplicated for each drug. 




were present in the 50づL added to each of the required wells. Serial drug dilutions were 
prepared using a 96 deep well mixing plate, with the drug being diluted in complete 
IMDM media. The drugs were prepared at twice the desired concentrations for the assay┸ to account for dilution once added to the のどづL of cells present in the wells┻ The 
plates were then incubated at 37°C/ 5% CO2 for 120 hours. 
 After this period of incubation┸ にのづL of MTT reagent was added to each well of 
the plate. MTT reagent was made up by diluting 0.5g of MTT (Universal Biologicals Ltd, 
Cambridge, UK, Ref 20395) in 250mL of PBS, and then filter sterilising this solution, 
before being stored at 4°C wrapped in foil. The plates were incubated at 37°C/ 5% CO2 after the addition of MTT for ね hours┸ before the addition of などどづL of a solution of 20% 
(w/v) Sodium Dodecyl Sulphate (SDS) in 1:1 Milli-Q H20:DMF (Dimethylformamide 
(DMF), acidified to pH 4.4. The plates were incubated at 37°C/ 5% CO2 overnight to 
allow for the lysis of the cells and for the dissolution of formazan. After this, the plates 
could be read in a plate reader (VICTOR X4, PerkinElmer, Waltham, MA, USA) to 
measure the absorbance at 600nm. 
 
3.3.3 Cell Counting 
After the cells had been disassociated from the flasks using Trypsin and re-suspended in media┸ a にどづL sample of suspended cells was used to establish cell counts and determine the average number of cells per mL┻ The にどづL of cell suspension was 
further diluted with にどづL of PBS┸ and ねどづL of ど┻ねガ Trypan Blue solution┻  At this point 
a haemocytometer was used to count the cells, viewed using a microscope (Olympus 
CKX53 inverted microscope, Olympus Life Sciences). Viable cells (appearing 
unstained) were counted from the four outer quadrants of the haemocytometer 
counting grid. In instances where cells were situated on boundary lines, only cells 
located on the inside boundaries were included.   
Figure 9 : The layout of a haemocytometer counting grid. Cells were counted in the four outer quadrants (with one 
highlighted in blue). Image source: Abcam.  
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To establish the average cell count per mL, the counts from each of the 4 
quadrants was averaged, multiplied by 104 and then multiplied by 4 to account for 
dilution in PBS and Trypan Blue.  
For MTT assays, the cells were seeded in the plate at a density of 5000 cells in のどづL added to each well┻ Therefore┸ the cell suspension was diluted such that there would be などど cells per づL┸ or などど┸どどど cells per mL┻ The cell count ゅin cells per mLょ was 
divided by 100,000 cells per mL to give the dilution factor needed to establish the 
appropriate ratio of cells:media. 
  
3.3.4 Analysis of MTT Data  
The MTT assay is able to establish the viability of cells relative to their untreated 
controls (MAX) based on the formation of formazan (and the subsequent absorbance 
levels at 600nm). In order to do this, the following calculation was used:  迎結健欠建件懸結 潔結健健 懸件欠決件健件建検 岫ガ岻 噺 畦決嫌剣堅決欠券潔結 伐 警荊軽警畦隙 伐 警荊軽  抜などど 
The mean background absorbance value produced in the media-only (MIN) wells 
was subtracted from each sample well, and also subtracted from the mean absorbance 
from the untreated wells (MAX). At this point the percentage viability of each sample 
relative to the untreated (MAX) cells could be calculated. These data were plotted to 
produce dose-response curves for each assay, and the IC50 and IC90 concentrations 
were calculated using the software, Calcusyn (Version 1.1, Biosoft, 1996). 
 
Figure 10 : A dose-response plot produced from an MTT assay of the EFO-27rCDDP2000 cell line against cisplatin, plotted 
using Microsoft Excel 2016. The IC50 for this assay (dashed red line) was calculated using Calcusyn as 17.44づM.     
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3.3.5 BET Inhibitor Pre-Treatment Assays  
Initially, MTT assays were conducted to assess the effect of the compounds as 
single-agents. This would be used to determine the sensitivities of the cell lines to 
cisplatin, oxaliplatin, and the BET inhibitors JQ1 and I-BET726. The BET inhibitors 
were subsequently used to pre-treat the cell lines, determining whether this altered 
the sensitivities to platinum drugs, and therefore these initial single-agent assays were 
also used to determine pre-treatment concentrations for JQ1 and I-BET726. 
The cells were pre-treated using the IC50 and IC10 concentrations of the BET 
inhibitors for each cell line. The IC10 was used to act as the minimum effective dose 
required to elicit a response, and would be used alongside the IC50 to assess the effect 
of pre-treatment dosage on the sensitivities to platinum drugs. 
Additionally, the effect of pre-treatment duration was investigated by incubating 
the cells with the BET inhibitor pre-treatments over 0hrs, 24hrs or 48hrs prior to the 
MTT assays against the platinum drugs.   
The MTT plates were prepared using the method outlined in Section 3.3.2, with 
the only modification being the addition of pre-treatment-only wells, which would not 
be treated with platinum drugs (marked as PTO in Figure 11). This reduced the dosing-
range of the platinum drugs to  7-point serial dilution across the 96-well plate.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B   PTO 1 2 3 4 5 6 7   
C   PTO 1 2 3 4 5 6 7   
D   PTO 1 2 3 4 5 6 7   
E   PTO 1 2 3 4 5 6 7   
F   PTO 1 2 3 4 5 6 7   
G   PTO 1 2 3 4 5 6 7   






Figure 11 : The modified arrangement for a  96 well plate MTT assay, used to investigate the effect of BET inhibitor pre-
treatment on the sensitivities to platinum drugs. The media-only (MIN) wells  are marked with a blue outline, and the 
untreated cell (MAX) wells with a red outline. The addition of pre-treatment-only control wells (marked PTO) means that 
the platinum drug would be investigated along a 7-point serial dilution (with triplicate wells labelled 1-7). The different 
plating conditions (pre-treatment + platinum drug) are represented with pink and green shading.  
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3.4 Statistical Analyses 
The software, Minitab 17 (version 17.3.1, Minitab Inc., 2016), was used to 
conduct all of the statistical analyses used in this study.  Statistical tests of the IC50 
and IC90 data were conducted to assess for differences in the responses of parental 
and resistant cell lines, or between compounds (e.g. JQ1 and I-BET726). 
When a single comparison was being conducted, for example comparing the 
IC50 of oxaliplatin between the parental UKF-NB-3 and oxaliplatin-resistant cell lines, 
a two-sample T-test was conducted. 
When multiple comparisons would be made, for example when comparing the 
effects of multiple drugs against both parental and resistant cell lines, the data was 
instead tested using a two-way Analysis of Variance (ANOVA). This was followed by 
post-hoc testing by Tukey╆s pairwise comparison┸ which compares the means of every 
experimental treatment, and uses 95% confidence intervals to identify means which 
differ beyond the boundaries of the expected standard error. Statistically different 
means are then assigned into groups, which are denoted in my figures with letters. 




















4.1 Characterisation of Platinum Compounds as Single-Agents 
4.1.1 Neuroblastoma 
The parental UKF-NB-3 and oxaliplatin-resistant UKF-NB-3rOXALI2000 cell lines 
were both tested against oxaliplatin, using the MTT viability assay (Section 3.3). These 
assays were used to characterise their sensitivities to the compound via the generation 
of dose-response profiles, establish IC50 and IC90 concentrations. Resistance-factors 
were also calculated, which is the fold-change in the IC50 of a drug in the resistant cell 
line, compared to the IC50 in the parental cell line. Figure 12 shows these data plotted 
for the UKF-NB-3 cell lines. 
It can be seen from the dose response curves (Figure 12A) that the UKF-NB-
3rOXALI2000 cell line is able to retain viability at substantially higher concentrations 
than the parental cell line. This is perhaps most evident when the concentration of oxaliplatin approaches なづM┸ which would be sufficient to reduce the parental cell line 
to 0% viability, whereas the oxaliplatin-resistant cell line exhibited approximately 90% 
viability. 
The mean IC50 and IC90 concentrations of oxaliplatin against the UKF-NB-3 cell 
lines are plotted in Figure 12B. The mean IC50 of oxaliplatin against the UKF-NB-
3rOXALI2000 cell line ゅぬ┻ひのづMょ was significantly higher than when the drug was tested 
against parental UKF-NB-3 cells (0.3ねづMょ (t(4)= 27.21, p<0.001), as determined by 
two-sample T-test. Likewise the UKF-NB-3rOXALI2000 cell line has a significantly higher 
IC90 of oxaliplatin (6.58づMょ than the parental cell line (0.41づMょ (t(4)= 32.41, 
p<0.001). 
Figure 12C illustrates the fold-changes (relative to the parental cell line) in the 
IC50 and IC90 of oxaliplatin against the UKF-NB-3 cell lines. A cell line exhibiting a 
resistance factor equal or above 2 is considered to be resistant to a compound. The 
oxaliplatin-resistant cell line had a resistance factor of 12.01 when the IC50 was 
compared, and a factor of  15.95 when the IC90 was compared. 
These data would serve as the baseline when investigating the effect of BET 
inhibitor pre-treatment on the sensitivity of the UKF-NB-3 cell lines to oxaliplatin. Any 
changes in the dose-response, IC50 or IC90, or resistance factor would be compared 












Figure 12 : Drug sensitivity profiling of the parental neuroblastoma UKF-NB-3 PTL cell line and oxaliplatin-resistant 
cell line UKF-NB-3rOXALI2000 against oxaliplatin, investigated by MTT assay.  A) Dose-response curves of oxaliplatin 
against UKF-NB-3 PTL (blue) and UKF-NB-3rOXALI2000 (red) B) Mean IC50 and IC90 of oxaliplatin for each cell line. 
UKF-NB-3rOXALI2000 had a significantly higher IC50 (t(4)= 27.21, p<0.001) and IC90 (t(4)= 32.41, p<0.001) than UKF-
NB-3 PTL, determined by two-sample T-test. C) The factor of resistance against oxaliplatin seen in the neuroblastoma 
cell lines. This is calculated as the fold difference between the IC50 or IC90, compared to that seen in the parental cell 

































































4.1.2 Ovarian Cancer 
As with the neuroblastoma UKF-NB-3 cell lines, the ovarian cancer COLO-704, 
EFO-21 and EFO-27 cell lines were all tested using the MTT viability assay, against 
cisplatin rather than oxaliplatin. These assays would again be used to characterise their 
baseline sensitivities to cisplatin via the generation of dose-response profiles, IC50 and 
IC90 concentrations, and resistance-factors. These data are plotted successively in 
Figure 13 (COLO-704),  Figure 14 (EFO-21), and  Figure 15 (EFO-27).  
The dose response curves of cisplatin against the  ovarian cancer cell lines are 
plotted in segment A of each cell line╆s respective figures┻ As with the UKF-NB-
3rOXALI2000 cells, each cisplatin-resistant ovarian cancer cell line was able to remain 
comparatively viable at concentrations which would be largely inhibitory to their 
parental counterpart cell line. 
The mean IC50 and IC90 concentrations of cisplatin against each ovarian cancer 
cell line are plotted in segment B. As with the neuroblastoma cell lines, there was a 
significant difference in the IC50 and IC90 concentrations of cisplatin between the 
parental and resistant cell lines. The statistical outputs of each two-sample T-test are 
given in the figure caption for each cell line, with the levels of significance also 
presented as asterisks on each figure. For 2 of the 3 sets of cell lines (COLO-704 and 
EFO-21), the difference in IC90 had lower statistical significance than the difference in 
IC50. This could be explained by the fact that the IC90 of cisplatin appears more 
variable, with greater standard deviation than the IC50. 
This variability in the IC90 of cisplatin can also be seen in segment C, which 
illustrates the fold-changes (relative to the parental cell line) in the IC50 and IC90 of 
cisplatin against the three ovarian cancer cell lines. Across all sets of cell lines we see 
that the resistance factor is above the 2-fold threshold used to determine resistance. 
As with the neuroblastoma UKF-NB-3 cell lines, these data would serve as the 
baseline for investigating the effect of BET inhibitor pre-treatment on the sensitivity of 






































































Figure 13 : Drug sensitivity profiling of the parental ovarian cancer COLO-704 PTL cell line and cisplatin-resistant 
cell line COLO-704rCDDP1000 against cisplatin, investigated by MTT assay.  A) Dose-response curves of cisplatin against 
COLO-704 PTL (blue) and COLO-704rCDDP1000 (red) B) Mean IC50 and IC90 of cisplatin for each cell line. COLO-
704rCDDP1000 had a significantly higher IC50 (t(4)= 8.21, p=0.001) and IC90 (t(4)= 5.48, p=0.005) than COLO-704 
PTL, as determined by two-sample T-test. C) The factor of resistance against cisplatin seen in the COLO-704 cell lines. 
This is calculated as the fold difference between the IC50 or IC90, compared to that seen in the parental cell line. A 



































































Figure 14 : Drug sensitivity profiling of the parental ovarian cancer EFO-21 PTL cell line and cisplatin-resistant cell 
line EFO-21rCDDP2000 against cisplatin, investigated by MTT assay.  A) Dose-response curves of cisplatin against EFO-
21 PTL (blue) and EFO-21rCDDP2000 (red) B) Mean IC50 and IC90 of cisplatin for each cell line. EFO-21rCDDP2000 had 
a significantly higher IC50 (t(4)= 31.51, p<0.001) and IC90 (t(4)= 4.99, p=0.008) than EFO-21 PTL, as determined by 
two-sample T-test. C) The factor of resistance against cisplatin seen in the EFO-21 cell lines. This is calculated as the 
fold difference between the IC50 or IC90, compared to that seen in the parental cell line. A threshold at 2-fold resistance 





































































Figure 15 : Drug sensitivity profiling of the parental ovarian cancer EFO-27 PTL cell line and cisplatin-resistant cell 
line EFO-27rCDDP2000 against cisplatin, investigated by MTT assay.  A) Dose-response curves of cisplatin against EFO-
27 PTL (blue) and EFO-27rCDDP2000 (red) B) Mean IC50 and IC90 of cisplatin for each cell line. EFO-27rCDDP2000 had 
a significantly higher IC50 (t(4)= 6.82, p=0.002) and IC90 (t(4)= 5.02, p=0.007) than EFO-27 PTL, as determined by 
two-sample T-test. C) The factor of resistance against cisplatin seen in the EFO-27 cell lines. This is calculated as the 
fold difference between the IC50 or IC90, compared to that seen in the parental cell line. A threshold at 2-fold resistance 
(dashed line) is used to discriminate whether or not a cell line is resistant to a compound.   
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4.2 Characterisation of BET Inhibitors as Single-Agents 
4.2.1 Neuroblastoma 
MTT assays were used to determine the sensitivities of the neuroblastoma cell 
lines to the BET inhibitors, JQ1 and I-BET726, as single-agents. These assays were also 
used to determine the IC10 and IC50 concentrations of each drug, which would later 
be used as pre-treatment dosages. 
The dose-response curves for the BET inhibitors against the UKF-NB-3 parental 
cell line are plotted in Figure 16A, with the dose-responses of the UKF-NB-3rOXALI2000 
cell line are plotted in Figure 16B. The parental and oxaliplatin-resistant cell line both 
appear to respond very similarly to the BET inhibitors, and additionally there does not 
seem to be a notable difference in the profiles of the two compounds compared to each 
other.  
The mean IC50 and IC90 concentrations of the BET inhibitors against each cell 
line are plotted in Figure 16C. These data were tested using a two-way Analysis of 
Variance (ANOVA) with post-hoc Tukey╆s pairwise comparison┸ using individual 95% 
confidence intervals. These tests yielded no significant difference in the IC50 of the BET 
inhibitors against either cell line, and only the IC90╆s of UKF-NB-3 treated with I-
BET726 and UKF-NB-3rOXALI2000 treated with JQ1 were found to be significantly different. 
However, analysis using pooled cell line data found significant differences between JQ1 
and I-BET726 at both IC50 (F(1,16)=5.78, p=0.029) and IC90 (F(1,16)=5.45, p=0.033).   
As described in Section 3.3.5, JQ1 and I-BET726 would be used as pre-treatments 
to investigate whether BET inhibition would alter the sensitivity of these cell lines to 
oxaliplatin. The mean IC10 and IC50 concentrations of the BET inhibitors, which would 





IC10 (nM) IC50 (nM) IC10 (nM) IC50 (nM) 
UKF-NB-3 PTL 1.52 69.98 1.25 114.42 
UKF-NB-3rOXALI2000 4.55 85.67 7.20 98.19 
Table 1 : The mean IC10 and IC90 concentrations (in nM) of the BET inhibitors, JQ1 and I-BET726, against the UKF-NB-
3 parental and oxaliplatin-resistant cell lines. These concentrations would be used as pre-treatment doses, prior to 





















































































CUKF-NB-3 PTL + JQ1 UKF-NB-3 PTL + I-BET726
UKF-NB-3rOXALI2000 + JQ1 UKF-NB-3rOXALI2000 + I-BET726
N.S. 
Figure 16 : Characterisation of the BET inhibitors, JQ1 and I-BET726, against the UKF-NB-3 PTL and UKF-NB-
3rOXALI2000 cell lines , investigated by MTT assay.  A) Dose-response curves of  the UKF-NB-3 PTL  cell line after being 
treated with JQ1 (darker blue) and I-BET726 (lighter blue) B) Dose-response curves of  the UKF-NB-3rOXALI2000 cell 
line after being treated with JQ1 (darker red) and I-BET726 (lighter red)  C) The mean IC50 and IC90s of the BET 
inhibitors against the parental and oxaliplatin-resistant cell lines. Statistical testing using two-way ANOVA with post-
hoc Tukey╆s pairwise comparison┸ using individual ぶひグ confidence intervals┸ yielded no significant difference in the 
IC50 of the BET inhibitors against either cell line. The groupings of the IC90 comparison are presented as letters (A 
and B). Means that do not share a letter are significantly different.   
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4.2.2 Ovarian Cancer 
The sensitivities of the ovarian cancer cell lines to JQ1 and I-BET726 as single-
agents were tested using MTT assays. The data for these assays are plotted successively 
in Figure 17 (COLO-704),  Figure 18 (EFO-21), and  Figure 19 (EFO-27). 
The dose-response curves for the BET inhibitors against the parental cell line are 
plotted in segment A of each figure, with the dose-responses of the cisplatin-resistant cell 
line plotted in segment B. The parental and cisplatin-resistant counterpart cell lines 
appear to respond very similarly to the two BET inhibitors. It would seem that JQ1 is 
slightly more effective than I-BET726 in these cell lines, however the difference is 
reasonably small, and the responses seem much more variable than the UKF-NB-3 
lines.  
The mean IC50 and IC90 concentrations of the BET inhibitors against each cell 
line are plotted in segment C. Two-way Analysis of Variance (ANOVA) with post-hoc Tukey╆s pairwise comparison yielded no significant difference in the IC50 or IC90 
between the BET inhibitors and between the parental and cisplatin-resistant cell lines. 
Analyses of each pair of cell lines only found a significant difference at the IC50s of EFO-
27, with the pooled response to BET inhibition significantly differing between the 
parental and cisplatin-resistant cell lines (F(1,8)=6.44, p=0.035).     
The mean IC10 and IC50 concentrations of JQ1 and I-BET726 against each 
ovarian cancer cell line are presented (in nM) in Table 2. As with the neuroblastoma 




IC10 (nM) IC50 (nM) IC10 (nM) IC50 (nM) 
COLO-704 PTL 3.49 193.31 6.04 545.41 
COLO-704rCDDP1000 2.43 116.95 6.68 351.62 
EFO-21 PTL 1.96 513.54 5.48 336.85 
EFO-21rCDDP2000 1.18 326.01 3.26 689.60 
EFO-27 PTL 3.26 515.84 16.66 597.77 
EFO-27rCDDP2000 1.85 165.59 9.62 371.90 
Table 2 : The mean IC10 and IC90 concentrations (in nM) of the BET inhibitors, JQ1 and I-BET726, against the parental 
and cisplatin-resistant ovarian cancer cell lines. These concentrations would be used as pre-treatment doses, prior to 











































































CCOLO-704 PTL + JQ1 COLO-704 PTL + I-BET726
COLO-704rCDDP1000 + JQ1 COLO-704rCDDP1000 + I-BET726
N.S. 
N.S. 
Figure 17 : Characterisation of the BET inhibitors, JQ1 and I-BET726, against the COLO-704 PTL and COLO-
704rCDDP1000 cell lines , investigated by MTT assay.  A) Dose-response curves of  the COLO-704 PTL  cell line after being 
treated with JQ1 (darker blue) and I-BET726 (lighter blue) B) Dose-response curves of  the COLO-704rCDDP1000 cell 
line after being treated with JQ1 (darker red) and I-BET726 (lighter red)  C) The mean IC50 and IC90s of the BET 
inhibitors against the parental and cisplatin-resistant cell lines. Statistical testing using two-way ANOVA with post-
hoc Tukey╆s pairwise comparison┸ using individual ぶひグ confidence intervals┸ yielded no significant difference in the 












































































CEFO-21 PTL + JQ1 EFO-21 PTL + I-BET726
EFO-21rCDDP2000 + JQ1 EFO-21rCDDP2000 + I-BET726
N.S. 
N.S. 
Figure 18 : Characterisation of the BET inhibitors, JQ1 and I-BET726, against the EFO-21 PTL and EFO-21rCDDP2000 
cell lines , investigated by MTT assay.  A) Dose-response curves of  the EFO-21 PTL  cell line after being treated with 
JQ1 (darker blue) and I-BET726 (lighter blue) B) Dose-response curves of  the EFO-21rCDDP2000 cell line after being 
treated with JQ1 (darker red) and I-BET726 (lighter red)  C) The mean IC50 and IC90s of the BET inhibitors against 
the parental and cisplatin-resistant cell lines. Statistical testing using two-way ANOVA with post-hoc Tukey╆s pairwise 
comparison, using individual 95% confidence intervals, yielded no significant difference in the IC50 or IC90 of the BET 














































































CEFO-27 PTL + JQ1 EFO-27 PTL + I-BET726
EFO-27rCDDP2000 + JQ1 EFO-27rCDDP2000 + I-BET726
N.S. 
N.S. 
Figure 19: Characterisation of the BET inhibitors, JQ1 and I-BET726, against the EFO-27 PTL and EFO-27rCDDP2000 
cell lines , investigated by MTT assay.  A) Dose-response curves of  the EFO-27 PTL  cell line after being treated with 
JQ1 (darker blue) and I-BET726 (lighter blue) B) Dose-response curves of  the EFO-27rCDDP2000 cell line after being 
treated with JQ1 (darker red) and I-BET726 (lighter red)  C) The mean IC50 and IC90s of the BET inhibitors against 
the parental and cisplatin-resistant cell lines. Statistical testing using two-way ANOVA with post-hoc Tukey╆s pairwise 
comparison, using individual 95% confidence intervals, yielded no significant difference in the IC50 or IC90 of the BET 
inhibitors against either cell line.   
49 
 
4.3 Pre-Treatment MTT Assays 
4.3.1 Neuroblastoma 
4.3.1.1 UKF-NB-3 Pre-Treated Using the IC10 of the BET Inhibitors 
The UKF-NB-3 cell lines were pre-treated using the IC10 of the BET inhibitors 
(established in Section 4.2.1), and were incubated with this pre-treatment dosage over 
0, 24, or 48 hours prior to conducting an MTT assay against oxaliplatin. 
The dose-response curves from these assays are plotted in Figure 20A-C, with the 
pre-treatment time increasing from A to C. It can be seen from these plots that the IC10, 
when administered immediately prior to oxaliplatin (0 hours), does not seem to 
dramatically alter the sensitivity to oxaliplatin. This is particularly evident in the 
parental cell line, but there is only a small change seen in the resistant, UKF-NB-
3rOXALI2000, cell line. However, as the pre-treatment duration increases, the dose-
response curves shift to the left, becoming more sensitive to oxaliplatin, and this effect 
is most apparent in the UKF-NB-3rOXALI2000 cell line. 
The IC50 and resistance factor values produced in these assays are plotted in 
Figure 21A-C, again with the pre-treatment duration increasing from A to C. After a 0-
hour pre-treatment, there is no significant difference in the IC50 of oxaliplatin between 
pre-treated cells and their initial responses to oxaliplatin without pre-treatment, with 
the only difference seen between UKF-NB-3 and UKF-NB-3rOXALI2000 cell lines.  
As the pre-treatment time increased to 24 and 48 hours, the IC50 of oxaliplatin 
against the UKF-NB-3rOXALI2000 cell line is significantly reduced compared to the 
baseline IC50. In this resistant cell line, a significant difference in IC50 was also seen 
between JQ1- and I-BET726-pre-treated cells.   
In the parental cell line, even as the pre-treatment duration increased to 48 hours, 
the mean IC50 of oxaliplatin did not differ sufficiently from the initial IC50 (without 
pre-treatment) to achieve statistical significance, and no difference was observed 





















































UKF-NB-3 PTL + JQ1 UKF-NB-3rOXALI2000 + JQ1
UKF-NB-3 PTL + I-BET726 UKF-NB-3rOXALI2000 + I-BET726
Pre-treatment: 
IC10 for 48hrs
Figure 20: Dose-response curves of the UKF-NB-3 PTL (blue) and UKF-NB-3rOXALI2000 (red) cell lines to oxaliplatin 
after pre-treatment using the IC10 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). The dose-
response curves from the initial characterisation assays are included as solid lines, with the JQ1-pre-treated assays 
depicted as the darker dashed lines, and I-BET726-pre-treated depicted with  lighter dashed lines. The unattached 
points at the left of each graph represent the viabilities of the pre-treatment-only samples, which were not exposed to 




























UKF-NB-3 PTL + JQ1 UKF-NB-3rOXALI2000 + JQ1
UKF-NB-3 PTL + I-BET726 UKF-NB-3rOXALI2000 + I-BET726
Pre-treatment: 




























UKF-NB-3 PTL + JQ1 UKF-NB-3rOXALI2000 + JQ1
UKF-NB-3 PTL + I-BET726 UKF-NB-3rOXALI2000 + I-BET726
Pre-treatment: 
IC10 for 24hrs 
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 Figure 21: Mean IC50 and Resistance Factors of the UKF-NB-3 PTL (blue) and UKF-NB-3rOXALI2000 (red) cell lines to 
oxaliplatin after pre-treatment using the IC10 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). 
Statistical testing by two-way ANOVA with post-hoc Tukey╆s pairwise comparison┸ using individual ぶひグ confidence 
intervals, yielded no significant difference in the IC50 of oxaliplatin when cells were pre-treated for 0 hours, however 
after 24 and 48 hours, significant differences were seen in the UKF-NB-3rOXALI2000 cell line, but not in UKF-NB-3 PTL. 
The groupings of the IC50 comparison are presented as letters (A-D). Means that do not share a letter are significantly 




























































































































4.3.1.2 UKF-NB-3 Pre-Treated Using the IC50 of the BET Inhibitors 
The pre-treatment dose of the BET inhibitors was increased to their IC50 
(established in Section 4.2.1), and again the cells were incubated with this pre-
treatment dosage over 0, 24, or 48 hours prior to conducting an MTT assay against 
oxaliplatin.  
The dose-response curves from these assays are plotted in Figure 22A-C, with the 
pre-treatment time increasing from A to C. The IC50 of the BET inhibitors, when 
administered immediately prior to oxaliplatin (0 hours), was able to induce a change 
in the sensitivity of the UKF-NB-3rOXALI2000 cell line to oxaliplatin. The parental cell 
line did not seem to respond the same, with very little change after the 0 hour pre-
treatment. Similarly to when the IC10 was used, as the pre-treatment duration 
increases, the dose-response curves of both cell lines shift to the left, becoming more 
sensitive to oxaliplatin, and again this effect is most apparent in the UKF-NB-
3rOXALI2000 cell line. 
The IC50 and resistance factor values produced in these assays are plotted in 
Figure 23A-C, again with the pre-treatment duration increasing from A to C. The 0-hour 
pre-treatment was able to induce a significant difference in the IC50 of oxaliplatin in 
the UKF-NB-3rOXALI2000 cells. The IC50s and resistance factors of UKF-NB-3rOXALI2000 
in these conditions were lower than those produced when the cells had been pre-
treated for 48 hours using the IC10 of the BET inhibitors.   
As the pre-treatment time increased to 24 and 48 hours, the IC50 of oxaliplatin 
against the UKF-NB-3rOXALI2000 cell line continues to decrease. When the cells had 
been pre-treated for 48 hours prior to the MTT assay, the resistance factors of pre-
treated cells are reduced to the extent that they are very close to the threshold used to 
discriminate drug-resistance. Statistical testing using two-way ANOVA with post-hoc Tukey╆s pairwise comparison found no significant difference between the baseline 
IC50 of the parental cell line and UKF-NB-3rOXALI2000 cells pre-treated for 48 hours 
with JQ1.      
Again in the parental cell line, as the pre-treatment duration increased to 48 
hours, the mean IC50 of oxaliplatin did not differ sufficiently from the initial IC50 
(without pre-treatment) to achieve statistical significance. No significant difference 
was observed between the BET inhibitors, and this was seen in both cell lines and 
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UKF-NB-3 PTL + JQ1 UKF-NB-3rOXALI2000 + JQ1
UKF-NB-3 PTL + I-BET726 UKF-NB-3rOXALI2000 + I-BET726
Pre-treatment: 
IC50 for 48hrs 
Figure 22: Dose-response curves of the UKF-NB-3 PTL (blue) and UKF-NB-3rOXALI2000 (red) cell lines to oxaliplatin 
after pre-treatment using the IC50 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). The dose-
response curves from the initial characterisation assays are included as solid lines, with the JQ1-pre-treated assays 
depicted as the darker dashed lines, and I-BET726-pre-treated depicted with  lighter dashed lines. The unattached 
points at the left of each graph represent the viabilities of the pre-treatment-only samples, which were not exposed to 



































































































































Figure 23: Mean IC50 and Resistance Factors of the UKF-NB-3 PTL (blue) and UKF-NB-3rOXALI2000 (red) cell lines to 
oxaliplatin after pre-treatment using the IC50 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). 
Statistical testing by two-way ANOVA with post-hoc Tukey╆s pairwise comparison┸ using individual ぶひグ confidence 
intervals, yielded significant differences in the IC50 of oxaliplatin when UKF-NB-3rOXALI2000 cells were pre-treated 
over 0, 24 and 48 hours, but no significant differences were seen in the  UKF-NB-3 PTL cell line. The groupings of the 
IC50 comparison are presented as letters (A-D). Means that do not share a letter are significantly different. It can be 
seen from these groupings that, after 48 hour pre-treatment with JQ1, the IC50 of oxaliplatin against UKF-NB-
3rOXALI2000 is not significantly different from the untreated UKF-NB-3 PTL cell line. 
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4.3.2 Ovarian Cancer 
4.3.2.1 COLO-704 Pre-Treated Using the IC10 of the BET Inhibitors 
The COLO-704 ovarian cancer cell lines were pre-treated using the IC10 of the 
BET inhibitors (Section 4.2.2) over 0, 24, or 48 hours prior to conducting an MTT assay 
against cisplatin. 
The dose-response curves from these assays are plotted in Figure 24A-C, with the 
pre-treatment time increasing from A to C. The IC10 of the BET inhibitors, when 
administered immediately prior to cisplatin (0 hours), produced a minimal effect in 
both the parental and cisplatin-resistant cell line, with the data only slightly deviating 
from the initial sensitivities.  As the pre-treatment duration increases, the sensitivity of 
both cell lines increases, which is particularly noticeable at the higher concentrations 
of cisplatin. The two BET inhibitors produced very similar results, with largely 
overlapping dose-response curves.   
The IC50 and resistance factor values produced in these assays are plotted in 
Figure 25A-C, again with the pre-treatment duration increasing from A to C. The 0-hour 
pre-treatment was able to induce a significant difference in the IC50 of cisplatin in the 
COLO-704rCDDP1000 cells, and was able to decrease the resistance factor markedly. As 
the pre-treatment time increased to 24 and 48 hours, the IC50 of cisplatin against the 
cisplatin-resistant cell line continues to decrease. After a 48-hour pre-treatment, the 
resistance factor of COLO-704rCDDP1000 cells  had decreased from an initial near 6-fold 
resistance, down to approximately 4-fold. No significant difference was observed 
between the IC50s produced after either JQ1 or I-BET726, across all pre-treatment 
durations.      
The IC50s of the COLO-704 PTL cell line did not significantly differ after pre-
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COLO-704 PTL + JQ1 COLO-704rCDDP1000 + JQ1
COLO-704 PTL + I-BET726 COLO-704rCDDP1000 + I-BET726
Pre-treatment: 
IC10 for 48hrs 
Figure 24: Dose-response curves of the COLO-704 PTL (blue) and COLO-704rCDDP1000 (red) cell lines to cisplatin after 
pre-treatment using the IC10 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). The dose-response 
curves from the initial characterisation assays are included as solid lines, with the JQ1-pre-treated assays depicted as 
the darker dashed lines, and I-BET726-pre-treated depicted with lighter dashed lines. The unattached points at the 
left of each graph represent the viabilities of the pre-treatment-only samples, which were not exposed to cisplatin 

























































































































Figure 25: Mean IC50 and Resistance Factors of the COLO-704 PTL (blue) and COLO-704rCDDP1000 (red) cell lines to 
cisplatin after pre-treatment using the IC10 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). 
Statistical testing by two-way ANOVA with post-hoc Tukey╆s pairwise comparison┸ using individual ぶひグ confidence 
intervals, yielded no significant difference in the IC50 of cisplatin against the parental cells across all pre-treatment 
durations. Conversely, significant differences were seen in the COLO-704rCDDP1000 cell line across all pre-treatment 
durations. The groupings of the IC50 comparison are presented as letters (A-D). Means that do not share a letter are 
significantly different.    
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4.3.2.2 COLO-704 Pre-Treated Using the IC50 of the BET Inhibitors 
The dose-response curves of cisplatin against the COLO-704 cell lines after pre-
treatment with the IC50 of the BET inhibitors are plotted in Figure 26A-C. When the 
BET inhibitors were administered immediately prior to cisplatin (0 hours), we again 
only notice small changes in the sensitivities of both the parental and cisplatin-
resistant cell lines.  As the pre-treatment duration increases, both cell lines showed 
increased sensitivity, with a noticeable change between the 0- and 24-hour assays. 
Another common feature is that the two BET inhibitors produced very similar results. 
JQ1 appears to increase sensitivity to a slightly greater extent than I-BET726, but there 
is a large degree of overlap between the datasets.   
The IC50 and resistance factor values produced in these assays are plotted in 
Figure 27A-C. The 0-hour pre-treatment was able to induce a significant difference in 
the IC50 of cisplatin in the COLO-704rCDDP1000 cells, and was able to decrease the 
resistance factor to a similar degree to that seen when the COLO-704rCDDP1000 cells 
were pre-treated with the IC10 over 24 hours. As the pre-treatment time increased to 
24 and 48 hours, the IC50 of cisplatin against the COLO-704rCDDP1000 cell line 
continues to decrease. After a 48-hour pre-treatment, the COLO-704rCDDP1000 cells 
demonstrated marked reductions in their IC50 and resistance factor values. When JQ1 
was used as a pre-treatment, no significant difference was calculated between the IC50 
of COLO-704rCDDP1000 and the baseline COLO-704 PTL sensitivity..      
As was seen previously, no significant difference was observed between the IC50s 
produced from the individual BET inhibitor pre-treatments, across all durations. 
Analyses of the mean IC50s of the parental cell line calculated no significant difference 
(relative to the baseline IC50 of cisplatin) after pre-treatment with either BET-
inhibitor, over any duration of pre-treatment. It can be seen, however, that as the pre-
treatment time increases, there is a decrease in the mean IC50 of cisplatin against the 
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COLO-704 PTL + I-BET726 COLO-704rCDDP1000 + I-BET726
Pre-treatment: 
IC50 for 48hrs 
Figure 26: Dose-response curves of the COLO-704 PTL (blue) and COLO-704rCDDP1000 (red) cell lines to cisplatin after 
pre-treatment using the IC50 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). The dose-response 
curves from the initial characterisation assays are included as solid lines, with the JQ1-pre-treated assays depicted as 
the darker dashed lines, and I-BET726-pre-treated depicted with lighter dashed lines. The unattached points at the 
left of each graph represent the viabilities of the pre-treatment-only samples, which were not exposed to cisplatin 




























































































































Figure 27: Mean IC50 and Resistance Factors of the COLO-704 PTL (blue) and COLO-704rCDDP1000 (red) cell lines to 
cisplatin after pre-treatment using the IC50 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). 
Statistical testing by two-way ANOVA with post-hoc Tukey╆s pairwise comparison┸ using individual ぶひグ confidence 
intervals, yielded no significant difference in the IC50 of cisplatin against the parental cells across all pre-treatment 
durations. Conversely, significant differences were seen in the COLO-704rCDDP1000 cell line across all pre-treatment 
durations. The groupings of the IC50 comparison are presented as letters (A-D). Means that do not share a letter are 
significantly different. After a 48 hour pre-treatment of JQ1, the IC50 of cisplatin against COLO-704rCDDP1000 is not 
significantly different from the untreated parental cell line, and has a resistance factor below the two-fold threshold.    
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4.3.2.3 EFO-21 Pre-Treated Using the IC10 of the BET Inhibitors 
The EFO-21 cell lines were pre-treated using the IC10 of JQ1 and I-BET726, over 
0, 24, or 48 hours, producing the dose-response curves plotted in Figure 28A-C. When 
the BET inhibitors were administered immediately prior to cisplatin (0 hours), there 
was little-to-no effect seen in the EFO-21 PTL cell line.  As seen in the previous cell lines, 
there appears to be an improved response to cisplatin as the pre-treatment duration 
increases, and the responses to each BET inhibitor are very similar. 
The IC50 and resistance factor values produced in these assays are plotted in 
Figure 29A-C. The 0-hour pre-treatment was not able to induce a significant difference 
in the IC50 of cisplatin against either of the cell lines. As the pre-treatment time 
increased to 24 and 48 hours, the IC50 of cisplatin against the EFO-21rCDDP2000 cell 
line decreased to become significantly different from the baseline IC50.  In these assays, 
a significant difference was calculated between JQ1 and I-BET726 pre-treated cells. As 
the pre-treatment duration increases we see a decrease in the resistance factor of the 
EFO-21rCDDP2000 cell line, particularly so when the cells were pre-treated with JQ1.      
Another result which appears to be consistent between the cell lines is that the 
mean IC50 of the parental cell line was not statistically different after pre-treatment 
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EFO-21 PTL + JQ1 EFO-21rCDDP2000 + JQ1
EFO-21 PTL + I-BET726 EFO-21rCDDP2000 + I-BET726
Pre-treatment: 
IC10 for 48hrs 
Figure 28: Dose-response curves of the EFO-21 PTL (blue) and EFO21rCDDP2000 (red) cell lines to cisplatin after pre-
treatment using the IC10 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). The dose-response 
curves from the initial characterisation assays are included as solid lines, with the JQ1-pre-treated assays depicted as 
the darker dashed lines, and I-BET726-pre-treated depicted with lighter dashed lines. The unattached points at the 
left of each graph represent the viabilities of the pre-treatment-only samples, which were not exposed to cisplatin 



















































































































Figure 29: Mean IC50 and Resistance Factors of the EFO-21 PTL (blue) and EFO-21rCDDP2000 (red) cell lines to 
cisplatin after pre-treatment using the IC10 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). 
Statistical testing by two-way ANOVA with post-hoc Tukey╆s pairwise comparison┸ using individual ぶひグ confidence 
intervals, yielded no significant difference in the IC50 of cisplatin against the parental cells across all pre-treatment 
durations. Significant differences were seen in the EFO-21rCDDP2000 cell line across all pre-treatment durations and, 
after 24- and 48-hour pre-treatments, between the two BET inhibitors. The groupings of the IC50 comparison are 
presented as letters (A-D). Means that do not share a letter are significantly different.    
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4.3.2.4 EFO-21 Pre-Treated Using the IC50 of the BET Inhibitors 
The dose-response curves plotted in Figure 30A-C  show the EFO-21 cell lines 
response to cisplatin after being pre-treated using the IC50 of the BET inhibitors. These 
results seem to show more notable changes in the parental cell line, particularly as the 
pre-treatment duration increases┻ For example┸ a cisplatin concentration of に┻のづM 
produced a mean viability of 23.9% in the initial baseline assays. After pre-treatment 
with the BET inhibitors for 24 hours, this cisplatin concentration was sufficient to 
reduce the  mean viability to zero. Similarly, the sensitivity of the EFO-21rCDDP2000 was 
improved when the IC50 was used as a pre-treatment, with this effect improving as 
pre-treatment durations increased. 
Figure 31A-C depicts the IC50 and resistance factor values produced in these 
assays. As has been observed previously, the EFO-21rCDDP2000 cell line exhibits a 
steady decrease in its IC50 and resistance factor to cisplatin as the duration of pre-
treatment with BET inhibitors increases. With a 48-hour pre-treatment using the IC50 
of JQ1, the cisplatin-resistant cell line shows no significant difference to the baseline 
IC50 of the parental EFO-21 cell line. This 48-hour pre-treatment was able to reduce 
the resistance factor of the EFO-21rCDDP2000 cell line to the vicinity of the 2-fold 
threshold which is used to distinguish resistance.      
Interestingly, these assays may seem to show a decrease in the mean IC50 of the 
parental cell line as a consequence of pre-treatment with BET inhibitors. In the 24-hour 
pre-treatment assay, a statistically significant difference was observed between the 
JQ1-pre-treated cells and the initial baseline IC50. The mean IC50 of cisplatin does 
continue to decrease further ゅfrom  ど┻ばなづM to ど┻ねねづMょ as the pre-treatment duration 
increases to 48 hours. However, the responses from the 48-hour pre-treatment assays 
were more variable, and thus had a broader range of their 95% confidence intervals, 
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EFO-21 PTL + JQ1 EFO-21rCDDP2000 + JQ1
EFO-21 PTL + I-BET726 EFO-21rCDDP2000 + I-BET726
Pre-treatment: 
IC50 for 48hrs 
Figure 30: Dose-response curves of the EFO-21 PTL (blue) and EFO21rCDDP2000 (red) cell lines to cisplatin after pre-
treatment using the IC50 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). The dose-response 
curves from the initial characterisation assays are included as solid lines, with the JQ1-pre-treated assays depicted as 
the darker dashed lines, and I-BET726-pre-treated depicted with lighter dashed lines. The unattached points at the 
left of each graph represent the viabilities of the pre-treatment-only samples, which were not exposed to cisplatin 
























































































































Figure 31: Mean IC50 and Resistance Factors of the EFO-21 PTL (blue) and EFO-21rCDDP2000 (red) cell lines to 
cisplatin after pre-treatment using the IC50 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). 
Statistical testing  was conducted by two-way ANOVA with post-hoc Tukey╆s pairwise comparison┸ using individual 
95% confidence intervals. The groupings of the IC50 comparison are presented as letters (A-D). Means that do not 
share a letter are significantly different.  Only when pre-treated for 24 hours did the IC50 of cisplatin against the 
parental cell show significant differences. Significant differences were seen in the EFO-21rCDDP2000 cell line across 
nearly all pre-treatment conditions, with exception to those treated with I-BET726 for 0 hours.  
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4.3.2.5 EFO-27 Pre-Treated Using the IC10 of the BET Inhibitors 
The final set of ovarian cancer cell lines used in this study, EFO-27, was pre-
treated using the IC10 of the BET inhibitors, producing the dose-response curves to 
cisplatin which are depicted in Figure 32A-C. We again see this relationship between 
pre-treatment duration and the changes in sensitivity which has been seen in the other 
cell lines: a 0-hour pre-treatment using the IC10 produces a minimal change, through 
to  more tangible improvements after 48 hours.  
The IC50 and resistance factor values produced in these assays are plotted in 
Figure 33A-C. The 0-hour pre-treatment was not able to induce a significant difference 
in the IC50 of cisplatin against either of the cell lines. As the pre-treatment duration 
increased to 24 and 48 hours, the IC50 of cisplatin against the EFO-27rCDDP2000 cell 
line decreases,  becoming significantly different from the baseline IC50.  After a 48-
hour pre-treatment using the IC10 of the BET inhibitors, we see that the resistance 
factor of the EFO-27rCDDP2000 cell line nearly halves, decreasing from 10.34 to 5.18 
(after JQ1) or 6.58 (after I-BET726).      
Another result which has been consistent between the cell lines is that, while 
there may be small reductions in the mean IC50 of the parental cell line after pre-
treatment using the IC10 of  the BET-inhibitor, these changes were not substantial 
enough to be deemed statistically different from the baseline IC50 of cisplatin, over any 
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CEFO-27 PTL EFO-27rCDDP2000EFO-27 PTL + JQ1 EFO-27rCDDP2000 + JQ1
EFO-27 PTL + I-BET726 EFO-27rCDDP2000 + I-BET726
Pre-treatment: 
IC10 for 48hrs 
Figure 32: Dose-response curves of the EFO-27 PTL (blue) and EFO27rCDDP2000 (red) cell lines to cisplatin after pre-
treatment using the IC10 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). The dose-response 
curves from the initial characterisation assays are included as solid lines, with the JQ1-pre-treated assays depicted as 
the darker dashed lines, and I-BET726-pre-treated depicted with lighter dashed lines. The unattached points at the 
left of each graph represent the viabilities of the pre-treatment-only samples, which were not exposed to cisplatin 



























































































































Figure 33: Mean IC50 and Resistance Factors of the EFO-27 PTL (blue) and EFO-27rCDDP2000 (red) cell lines to 
cisplatin after pre-treatment using the IC10 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). 
Statistical testing by two-way ANOVA with post-hoc Tukey╆s pairwise comparison┸ using individual ぶひグ confidence 
intervals, yielded no significant difference in the IC50 of cisplatin against the parental cells across all pre-treatment 
durations. Significant differences were seen in the EFO-21rCDDP2000 cell line after 24- and 48-hour pre-treatments, , 
but no difference was found between the two BET inhibitors. The groupings of the IC50 comparison are presented as 
letters (A-D). Means that do not share a letter are significantly different.    
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4.3.2.6 EFO-27 Pre-Treated Using the IC50 of the BET Inhibitors 
The dose-response curves plotted in Figure 34A-C  show the viability of the EFO-
27 cell lines in response to cisplatin after being pre-treated using the IC50 of the BET 
inhibitors. Similarly to the EFO-21 cell lines, these results seem to show more 
prominent changes in the sensitivity of the parental cell line, in addition to the 
cisplatin-resistant lines. It seems that the most notable shifts in the dose-response 
curves occur from the 0- to 24-hour samples, with further changes seen between 24- 
and 48 hours, but to a lesser extent.  
Figure 35A-C depicts the IC50 and resistance factor values produced in these 
assays. When the EFO-27rCDDP2000 cells had been pre-treated for 0 hours, only JQ1 was 
found to induce a significant change in the IC50 of cisplatin, however as the pre-
treatment time increases both BET inhibitors induced significant changes. After a 48-
hour pre-treatment using the IC50 of BET inhibitors, the cisplatin-resistant cell line 
shows no significant difference to the baseline IC50 of the parental EFO-21 cell line. 
This 48-hour pre-treatment was able to reduce the resistance factor of the EFO-
27rCDDP2000 cell line from 10.34, to 3.06 (JQ1) or 3.61-fold resistance (I-BET726).      
Unlike the EFO-21 cell lines, there were no pre-treatment conditions which 
yielded statistically significant reductions in the IC50 of cisplatin against the EFO-27 
PTL cell line. When we assess the general trend of the IC50 data across the pre-
treatment durations, there does seem to be a reduction in the IC50 of cisplatin. For 
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Figure 34: Dose-response curves of the EFO-27 PTL (blue) and EFO27rCDDP2000 (red) cell lines to cisplatin after pre-
treatment using the IC50 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). The dose-response 
curves from the initial characterisation assays are included as solid lines, with the JQ1-pre-treated assays depicted as 
the darker dashed lines, and I-BET726-pre-treated depicted with lighter dashed lines. The unattached points at the 
left of each graph represent the viabilities of the pre-treatment-only samples, which were not exposed to cisplatin 






























































































































Figure 35: Mean IC50 and Resistance Factors of the EFO-27 PTL (blue) and EFO-27rCDDP2000 (red) cell lines to 
cisplatin after pre-treatment using the IC50 of the BET inhibitors over 0 hours (A), 24 hours (B), or 48 hours (C). 
Statistical testing by two-way ANOVA with post-hoc Tukey╆s pairwise comparison┸ using individual ぶひグ confidence 
intervals, yielded no significant difference in the IC50 of cisplatin against the parental cells across all pre-treatment 
durations. Significant differences were seen in the EFO-27rCDDP2000 cell line across nearly all pre-treatment durations, 
except for the 0-hour I-BET726 pre-treatment. No difference was found between the two BET inhibitors. The 
groupings of the IC50 comparison are presented as letters (A-D). Means that do not share a letter are significantly 




As discussed in my Introduction, resistance to platinum compounds is a major 
cause of treatment failure and reduced survival rates across a range of different 
cancers. The mechanisms of resistance are complex, affecting a hugely diverse array of 
cellular processes; and this range of mechanisms is only partly understood (Holohan 
et al., 2013; Shahzad et al., 2009).  There is consequently an apparent need for further 
insight into how platinum resistance emerges and is facilitated in tumours, and also a 
need for ways to inhibit this resistance formation and/or reverse this resistance in 
tumours.    
There is evidence to suggest that BET proteins have a role to play in oncogenesis. 
Overexpression of BET proteins seen in leukaemias and B-cell lymphomas, NUT 
midline carcinomas, and lung cancers (Florence & Faller, 2001; Wang & 
Filippakopoulos, 2015; Zhang et al., 2016), and BET proteins have also been seen to 
regulate many of the pathways which are implicated in platinum resistance.  
The aims of this study were to investigate whether BET inhibitors were able to 
inhibit the viability of parental and platinum-resistant neuroblastoma and ovarian 
cancer cell lines, and to see whether BET inhibitors would alter the sensitivities of 
these cell lines to platinum agents. 
 
5.1 Responses of Cell Lines to BET Inhibition 
5.1.1 Summary of Results 
When MTT assays were conducted against JQ1 and I-BET726 as single agents 
(Section 4.2), there were no substantial differences between the responses of the 
parental and platinum-resistant counterpart cell lines. This could suggest that the 
mechanisms able to drive considerable levels of resistance to platinum compounds in 
these cell lines do not appear to confer some degree of cross-resistance against the two 
BET inhibitors.  
There did, however, appear to be variation in the sensitivity of the different 
cancer cell lines to BET inhibition, particularly so when the response of the 
neuroblastoma UKF-NB-3 cell lines are compared to the ovarian cancer cell lines. For 
instance, the IC50s of JQ1 against UKF-NB-3 cell lines were found to be approximately 
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three times lower than those of the ovarian cell lines, which could suggest that there  
may be specific features of each tumour cell line which determine sensitivity.    
Despite the differences in the initial sensitivities of the cancer cell lines to BET 
inhibition, this investigation found that pre-treatment with BET inhibitors was able to 
increase the sensitivity of all of the platinum-resistant cell lines to their respective 
platinum drug. There were improvements (although only small) in the responses to 
platinum drugs even when the IC10 of the BET inhibitors, which was chosen to 
represent a minimal effective dose, was used as a pre-treatment. Each of the cell lines 
appeared to show improved responses to platinum compounds as the pre-treatment 
dosage was elevated, and as the pre-treatment duration was increased. It was also 
noticeable that, while BET inhibition was able to alter the dose-response and cause 
small decreases in the mean IC50 of the parental cell lines to platinum compounds, the 
most notable changes were observed in the platinum-resistant cell lines.   
 
5.1.2 Potential Mechanisms of Action 
It is not known precisely what is happening mechanistically as a result of BET 
inhibition in these cell lines, and I feel that will be an important area for future study 
(detailed further in Section 5.3). It is possible that, if BET proteins are influential in 
maintaining the anti-apoptotic, pro-survival phenotype seen in resistant cells via 
transcriptional regulation, the action of BET inhibitors could be able to nullify this 
response by inhibiting the transcription of these pro-survival genes. 
Of the possible explanations for my results, one of the most studied mechanisms 
is the ability of BET inhibitors to inhibit the MYC oncogene. Amplification of MYCN is 
frequently seen in neuroblastoma, particularly so in high-risk cases, and is considered 
to convey a poor prognosis for patients (Ambros et al., 2009).  Dysregulation of C-MYC 
is also a feature which is prevalent amongst high-grade ovarian carcinomas, which also 
show poorer patient survival rates (Plisiecka-Halasa et al., 2003).   
Of the cell lines used in this study, UKF-NB-3, EFO-21 have been found in studies 
to show elevated expression of MYC (Kotchetkov et al., 2005; Wiedemeyer et al., 2013). 
Interestingly, the Wiedemeyer (2013) study found that JQ1 was able to inhibit 
expression of C-MYC in the EFO-21 cell line, and further postulated that this could result 
in downstream inhibition of BRCA gene expression. BRCA1 and BRCA2 are both 
implicated as means of platinum resistance in ovarian cancers due to their role in DNA 
damage responses and repair (Sakai et al., 2008; Swisher et al., 2008). A study 
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investigating I-BET726 against a panel of neuroblastoma similarly found that BET 
inhibition reduced the expression of MYCN, as well as the anti-apoptotic BCL2 (Wyce 
et al., 2013). This study also used microarrays and qPCR to monitor the effects this 
would have on expression of downstream MYCN targets, finding downregulation of 
genes such as NME2, an inhibitor of differentiation which is prone to amplification in 
aggressive neuroblastomas.  
Beneficial effects of JQ1 paired with cisplatin have also been seen in the ovarian 
cancer cell line, A2780, with the combination resulting in increased sensitivity of the 
cisplatin resistant cell line (Khabele et al., 2013). In this study, however, there was no 
correlation between the inhibitory effects of JQ1 and a downregulation of MYC 
suggesting that there are other oncogenic targets of JQ1 which require identifying.   
In addition to their ability to downregulate MYC, BET inhibitors have also been 
found to elicit anti-tumour effects via alternative mechanisms. A study of lung 
adenocarcinoma cell lines (Lockwood et al., 2012) found that JQ1 was able inhibit these 
cell lines with high potency, giving an increased number of cells arrested at G0/G1 or 
undergoing apoptosis. JQ1 was not found to cause downregulation of MYC in these cell 
lines. JQ1 was able to inhibit expression of FOSL1, preventing the formation of the 
heterodimeric AP-1 transcription factor (by association with Jun) which regulates 
cellular processes such as differentiation, growth and proliferation, and apoptosis. It 
was found that JQ1 inhibited the recruitment of BRD4 to the enhancer site of FOSL1, 
where it would usually recruit p-TEFb and RNA Pol II for transcriptional elongation.  
Another example of a transcription factor which has been downregulated as a 
result of BET inhibition in tumour cells is FOXM1, which was seen to be inhibited in a  
panel of 28 ovarian cancer cell lines (Zhang, Ma et al., 2016), including the EFO-27 cell 
line which was used in my study. BET inhibition was found to induce cell cycle arrest 
and apoptosis across these cell lines without notable discrepancies, despite the fact 
that these cell lines were obtained from a diverse range of tumour types from different 
tissues.   
An interesting study by Klingbeil et al. (2016), which could possibly shed some 
light onto my own results, investigated the combination of JQ1 and cisplatin in a panel 
of KRAS-mutated non-small cell lung cancer cell lines as well as in mouse models. This 
research determined that expression of the apoptosis regulators c-FLIP and XIAP were 
largely dependent on BET activity. The study also found dose-dependent responses to 
BET inhibition, as well as changes associated with treatment length. At shorter 
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durations, cells showed predominantly cell cycle arrest, with increases in apoptosis 
after longer durations. Finally, the combination of JQ1 with cisplatin was seen to have 
beneficial effects, with cisplatin more effectively able to induce apoptosis in the 
absence of the downregulated negative regulators.     
Prior work conducted in the Michaelis research group, based at the University of 
Kent, used yeast (Saccharomyces cerevisae) models to assess the contribution of BDF1 
(an equivalent BET protein found in yeast) on the resistance to platinum compounds 
(Sanders, 2016 ‒ unpublished). This research found that つBdfの deletion strains showed 
inhibited growth and viability in the presence of platinum compounds, and this 
viability could be improved by reintroducing a BDF1 plasmid into the deletion strain. 
It was thought that by inhibiting the transcriptional activity of the deletion strain, BDF1 
inhibition would reduce the capacity of the cells to detect and mount a repair response 
to these DNA lesions. It was also postulated that, if the BDF proteins are able to modify 
the chromatin integrity, that inhibition may alter the accessibility of the DNA to the 
compounds, or the accessibility of the DNA to the repair machinery (Chua & Roeder, 
1995; Mymryk et al., 1995).   
 As mentioned in my Introduction, BRD4 in humans is able to interact with a 
number of chromatin regulators (such as NSD3, JMJD6, CHD4, and ATAD5) via their 
association with the extra-terminal (ET) domain (Rahman et al., 2011). One example 
of the role of these proteins is their ability to modify the methylation status of H3K36, 
a modification which is typically associated with transcriptionally active regions. 
Inhibition of BRD4 or NSD3 resulted in reduced methylation of H3K36 in the proximity 
of regulated genes. 
       Considering the role BET proteins have in regulating the structure of 
chromatin, it is possible that JQ1 or I-BET726 are able to inhibit these changes in 
chromatin structure, and produce altered methylation patterns in treated cells. 
Resistant cells might not able to recruit the necessary chromatin modifiers in response 
to cellular cues and stresses (such as platinum induced DNA damage), resulting in a 
lack of necessary gene activation for survival. As mentioned previously it is also 
possible that the chromatin, without such regulation of its structure, is more accessible 






5.2 Implications for Wider BET Inhibitor Research 
Currently, the BET inhibitors which are widely used in research, such as JQ1, are 
pan-BET inhibitors, showing high affinity for members across the BET family (BRD2, 
BRD3, BRD4, and the testis-specific BRDT). These may also exhibit affinity for other 
bromodomain-containing proteins (such as BRD8) due to their ability to competitively 
bind the acetyl-lysine recognition sites of the BD1 and BD2 bromodomains.  While both 
JQ1 and I-BET726 are both pan-BET inhibitors, the two compounds have different 
affinities for the individual BET proteins, and I-BET726 demonstrates a high affinity 
for BET-family members, but has a low affinity for the other BRD-containing proteins 
(Filippakopoulos & Knapp, 2014; Wyce et al., 2013). It could perhaps be these subtle 
affinity divergences which account for the minor differences in the effects induced by 
the two BET inhibitors as pre-treatments.     
Due to the promising pre-clinical research emerging regarding BET inhibition, 
there are a number of BET inhibitors currently in early phases of clinical trials 
(www.clinicaltrials.gov; Theodoulou et al., 2016). JQ1 is not currently being used in 
clinical trials because it was found to have a very short half-life in the body (a matter 
of hours), however a number of analogous compounds are currently in development 
which have been modified to improve bioavailability (Gallenkamp et al., 2014). JQ1 still 
remains a useful tool for pre-clinical research due to its high affinity for BET proteins, 
and it has a relatively large bank of pre-clinical research characterising its function 
across a range of tissue and disease types.   
Compounds are also in development which are specific to individual members of 
the BET family in the hope that these may be useful in characterising the individual 
contributions of these proteins. These might later provide a more targeted treatment 
strategy if there are disease states where an individual BET member exhibits 
pathogenic activity (Ferri et al., 2016). In addition, inhibitors have been developed 
which are specific to the individual bromodomains, such as olinone  which is BD1-
specific (Ntranos & Casaccia, 2015) and RVX-208, which is BD2-specific (Johansson et 
al., 2014).  
Due to the fact that BET inhibitor research is, in a sense, still in its infancy, without 
large volumes of data produced in clinical trials of humans, the results and conclusions 
from this research must be drawn with caution. It is hoped that more stable compounds 
will yield more prolonged half lives in the body, and therefore offer a more useful 
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depiction of BET inhibitor action in humans.  Although these compounds appear to be 
well tolerated in the mouse models of pre-clinical research, it is possible that BET 
inhibition could produce dose-limiting side-effects when used in human patients. The 
results of this study have demonstrated that BET inhibitors are able to induce notable 
changes in platinum-resistant cells, but as of yet these changes are not characterised. 
It might be possible that these changes could make the patient╆s healthy cells more 
susceptible to the cytotoxicity side-effects of platinum agents, again meaning that dose-
limiting toxicity might become an impeding factor. This is particularly the case when 
considering that platinum drugs can produce side-effects such as nephrotoxicity in 
their current treatment protocols.    
Another factor which would require consideration, based on the bioavailability 
of the BET inhibitors, is the timing of pre-treatments prior to administration of 
platinum compounds. Research by Johnsson et al. (1995) assessed the 
pharmacokinetics and tissue distribution of cisplatin in nude mice after injection with 
7.5 mg/kg cisplatin. This found that the maximal concentration of cisplatin would vary 
between different organs, blood, and the tumour itself. This study also recorded 
different lengths of time before the peak concentration was achieved varied in each of 
these sites, from 15 minutes in the kidneys and liver, through to a gradual accumulation 
over 1 week in the brain. While these results may seem obvious, this could be an 
important factor if you were to consider the therapeutic usage of BET inhibitors as pre-
treatments before treating with platinum drugs. The two doses would have to aligned 
such that the most effective pre-treatment duration is timed to coincide with the peak 
uptake of platinum at the particular site. The results of my study indicated that a longer 
pre-treatment time would induce the best response to the platinum agent, but the 
compound will need to be bioavailable sufficiently to provide an effective pre-
treatment prior to degradation and clearance from the tissues.   
Finally, there is also the possibility of chemoresistance to BET inhibitors such as 
JQ1 and I-BET726. Because the exact mechanisms of BET inhibitor action have yet to 
be fully elucidated, there is a lack of predictive biomarkers which may be indicative of 
sensitivity or resistance to BET inhibition (Helin & Dhanak, 2013). Nevertheless there 
have been studies which have observed resistance to BET inhibitors and characterised 
some of the potential mechanisms (Settleman, 2016). For instance, increased 
activation of the Wnt signalling pathway was observed in leukaemia cells lines, leading 
to proliferation and increased survival in the presence of JQ1 (Fong et al., 2015; Rathert 
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et al., 2015). Another study of triple-negative breast cancer cell lines found that, in 
paired cell lines which had been selected for resistance to JQ1, proteomic investigation 
observed that the transcriptional regulator MED1 bound more tightly with BRD4 in 
resistant cells than in sensitive cells (Shu et al., 2016) and so was not displaced by JQ1. 
This study implicated hyper-phosphorylation of BRD4 for the increased strength of 
binding, and this is attributable to decreased activity of a principal BRD4 serine 
phosphatase, PP2A, and the elevated activity of casein kinase 2 (CK2).  
 
5.3 Suggestions for Future Research 
As mentioned previously, the exact mechanism by which JQ1 and I-BET726 were 
able to induce the increases in sensitivity of the platinum-resistant cell lines are not yet 
known.  Transcriptomics, for instance RNA-Seq or microarray techniques,  could be 
used to ascertain the changes in the transcriptional profiles of these cell lines, to 
identify genes which are up- or downregulated before and after  BET inhibition in these cell lines┻ These potential ╅hits╆ could subsequently be validated using techniques such 
as quantitative PCR.  
It is also possible that BET inhibition is able to alter the accessibility of DNA to 
the platinum compounds. This could potentially be investigated by measuring the 
levels of DNA damage in these cell lines with and without pre-treatment using BET 
inhibitors.  As mentioned in my Introduction (Section 2.3.3), the phosphorylation of the 
histone H2A variant, H2AX, at Ser-なぬひ to generate ぐ-H2AX is a response to DNA lesions 
which creates a focus for DNA damage response signalling. (Kinner et al., 2008; Pabla et al┻┸ にどどぱょ┻ Consequently┸ ぐ-H2AX is a useful biomarker which is frequently used for 
the study of DNA damage and repair (Mah et al., 2010). Using western blotting, or 
immunocytochemisty with fluorescence microscopy, it could be possible to investigate 
whether BET inhibitor pre-treatment increases the presence of platinum-induced DNA 
damage foci by screening for the Ser-なぬひ phosphorylation of (にAX ゅぐ-H2AX). 
Finally, it may be possible that BET inhibitors are able to alter the sensitivity of 
cancer cell lines exhibiting resistance to other drug classes. Multidrug resistance is a 
major obstacle precluding successful treatment across many cancer types (Wu et al. 
2014).  BET inhibitors may be able to alter the sensitivity of cell lines to compounds 
with distinct mechanisms of action (such as vincristine, which inhibits mitotic spindle 
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assembly), thus potentially improving patient responses to multiple compounds within 
their treatment protocols. 
6. Concluding Remarks 
In this study we found that BET inhibitors are able to increase the sensitivity of 
platinum resistant neuroblastoma and ovarian cancer cell lines. The responses to 
platinum compounds were improved as pre-treatment concentration was increased, 
and as the pre-treatment duration was prolonged. The resistance levels of these cell 
lines were decreased to the extent that they approached threshold values used to 
distinguish resistance of a cell line to a compound.  
The mechanisms by which tumours can exhibit resistance to platinum 
compounds are very diverse, and regulate a number of cellular processes which are 
crucial for cell survival and proliferation. It is not known exactly which pathways and 
processes are altered as a result of BET inhibition, and so this would seem to be a useful 
topic for further research. 
These results provide support for the concept that BET inhibition may potentially 
be a useful strategy for improving treatment efficacy of neuroblastoma and ovarian 
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